mitomycin has been researched along with Peritoneal Neoplasms in 406 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated health-related quality of life (HRQOL) using patient-reported outcomes in subjects with mucinous appendiceal neoplasms who underwent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) as part of a randomized trial comparing mitomycin with oxaliplatin." | 9.34 | Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. ( Bartlett, DL; Levine, EA; Mansfield, P; McQuellon, R; Moaven, O; Russell, G; Shen, P; Stewart, JH; Votanopoulos, KI, 2020) |
| " This paper reports our study of the pharmacokinetics of mitomycin C (MMC) administered by intraperitoneal chemohyperthermic perfusion (ICHP) in patients with peritoneal carcinomatosis." | 9.11 | Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion. ( Cerretani, D; Cioppa, T; De Stefano, A; Giorgi, G; Marrelli, D; Nastri, G; Nencini, C; Pinto, E; Roviello, F; Urso, R, 2005) |
| "A prospective Phase II trial was carried out with 83 patients who had digestive tract cancer and peritoneal carcinomatosis to evaluate the tolerance and efficacy of IPCH with mitomycin C (MMC) associated with surgery." | 9.09 | Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. ( Beaujard, AC; Bienvenu, J; Caillot, JL; Francois, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Panteix, G; Vignal, J, 2000) |
| " 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin." | 9.09 | Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001) |
| "During heated intraperitoneal chemotherapy (HIPEC), neutropenia rates of 20 to 40% have been reported when mitomycin C (MMC) is dosed by weight or body surface area (BSA)." | 7.85 | Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C. ( Aycart, SN; Bhagwandin, S; Feferman, Y; Feingold, D; Kim, J; Labow, DM; Sarpel, U, 2017) |
| " Mitomycin C (MMC) is frequently used but not devoid of toxicity, of which the most common and feared is neutropenia." | 7.81 | Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy. ( Brigand, C; Brumaru, D; Kemmel, V; Lessinger, JM; Mercoli, HA; Meyer, N; Romain, B, 2015) |
| "Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)." | 7.80 | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 7.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "We performed a retrospective chart review of a prospective database for patients undergoing CS and IPHC with mitomycin C for peritoneal carcinomatosis from colorectal primary lesions between December 1991 and April 2002." | 7.72 | Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. ( Fleming, RA; Geisinger, KR; Hawksworth, J; Levine, EA; Loggie, BW; Lovato, J; Shen, P, 2004) |
| "Activated carbon particles adsorbing mitomycin C (MMC-CH) was administered to four patients with peritoneal carcinomatosis of gastric cancer into their abdominal cavities." | 7.72 | [Intraperitoneal chemotherapy against peritoneal carcinomatosis of gastric cancer with activated carbon particles adsorbing mitomycin C for four patients]. ( Chou, H; Fujita, Y; Hagiwara, A; Kawakami, S; Ohgaki, M; Shiomi, A; Takashina, K; Takenaka, A; Yamagishi, H, 2004) |
| "Intraperitoneal chemo-hyperthermia with mitomycin C was used to treat 28 patients with far advanced digestive adenocarcinoma and histologically confirmed peritoneal carcinomatosis." | 7.69 | Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. ( Banssillon, V; Bienvenu, J; Brachet, A; Burgard, G; Carry, PY; Gilly, FN; Guibert, B; Panteix, G; Salle, B; Sayag, AC, 1994) |
| " hyperthermic perfusion (IPHP) with mitomycin C (MMC) for treating recurrent colorectal cancer." | 7.69 | Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. ( Arnold, MW; Dumond, D; Martin, EW; Schneebaum, S; Staubus, A; Young, DC, 1996) |
| "Intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil has been used to rescue patients from peritoneal carcinomatosis after perforated cystadenocarcinoma of the large bowel or appendix." | 7.68 | Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. ( Jaffe, G; Landy, D; Pascal, R; Sugarbaker, PH, 1990) |
| "Patients with peritoneal carcinomatosis have a uniformly poor prognosis." | 6.71 | Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. ( Case, D; Fleming, R; Geisinger, KR; Hall, J; Levine, EA; Loggie, BW; McQuellon, R; Russell, G; Shen, P, 2003) |
| "A new drug dosage form comprising activated carbon particles adsorbing mitomycin C (MMC-CH) is designed to slowly release its components, and has affinity for the tumor surface and lymph nodes and a tendency to stay long in the local portion." | 6.66 | Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Clinical trials. ( Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T, 1987) |
| "Adverse events after HIPEC were estimated by common terminology criteria for adverse events version 5." | 5.91 | Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching A ( Guo, X; Li, Y; Lin, Y; Lv, J; Ruan, T; Shen, C; Tao, K; Wu, C; Xiang, F; Zeng, X, 2023) |
| "A total of 124 colorectal cancer patients who underwent CRS with HIPEC between March 2015 and January 2019 were evaluated." | 5.72 | Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis. ( Baik, SH; Jeon, Y; Kang, J; Lee, HW; Lee, SJ; Park, EJ, 2022) |
| " Because MMC is the preferred agent of choice used in CRS-HIPEC, future studies should investigate optimal MMC dosing and patient selection when splenectomy is performed to balance survival benefit with hematologic toxicities." | 5.62 | Pancytopenia after administration of hyperthermic intraperitoneal chemotherapy with mitomycin-C: local therapy and systemic toxicity. ( Chung, SY; Saif, MW; Shen, J; Wu, V, 2021) |
| "Colorectal peritoneal carcinomatosis (PC) is commonly treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)." | 5.48 | Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. ( Aalbers, AGJ; Boot, H; Huitema, ADR; Kok, NFM; van Eden, WJ; Woensdregt, K, 2018) |
| "Compare long-term outcomes in colorectal cancer (CRC) patients with peritoneal carcinomatosis (PC) treated with peritonectomy/HIPEC using oxaliplatin versus MMC." | 5.46 | Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. ( Huo, YR; Leung, V; Liauw, W; Morris, DL, 2017) |
| "This study evaluated health-related quality of life (HRQOL) using patient-reported outcomes in subjects with mucinous appendiceal neoplasms who underwent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) as part of a randomized trial comparing mitomycin with oxaliplatin." | 5.34 | Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. ( Bartlett, DL; Levine, EA; Mansfield, P; McQuellon, R; Moaven, O; Russell, G; Shen, P; Stewart, JH; Votanopoulos, KI, 2020) |
| "Mitomycin C was administered as a perfusate at 10 mg/l." | 5.32 | Treatment of peritoneal carcinomatosis in patients with digestive cancers with combination of intraperitoneal hyperthermia and mitomycin C. ( Banssillon, V; Bienvenu, J; Francois, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Panteix, G; Sadeghi-Looyeh, B; Sayag-Beaujard, AC; Vignal, J, 2004) |
| "Persistent or recurrent peritoneal carcinomatosis (PC) documented at second-look surgery has proved relatively refractory to second-line therapy." | 5.27 | Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery. ( Alberts, DS; Graham, V; Monk, BJ; Surwit, EA, 1988) |
| " Twenty-one patients with PC (12 gastric cancer, 5 colorectal cancer, 2 ovarian cancer, 1 pseudomyxoma peritonei, 1 malignant mesothelioma) were treated with CRS + HIPEC with hydroxycamptothecin 20 mg and mitomycin C 30 mg in 12,000 mL of normal saline at 43 +/- ." | 5.14 | Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. ( al-shammaa Hassan, AH; Li, Y; Liu, SY; Lu, YL; Yang, GL; Yang, XJ; Yonemura, Y; Zhang, JW, 2009) |
| "This study provides strong arguments indicating that IPCH with oxaliplatin is better tolerated than EPIC with mitomycin C and 5-FU, and is twice as efficient in curing residual peritoneal carcinomatosis measuring less than 1 mm." | 5.12 | Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. ( Benizri, E; Di Pietrantonio, D; Elias, D; Malka, D; Menegon, P; Raynard, B, 2007) |
| "The aim of this study was to evaluate the activity and toxicity of a combination regimen of CPT-11 and mitomycin-c as second-line chemotherapy for pretreated patients with advanced, metastatic, or both, gastric adenocarcinoma." | 5.11 | Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). ( Battaglia, C; Colucci, G; Di Bisceglie, M; Gebbia, N; Gebbia, V; Giuliani, F; Maiello, E; Molica, S; Vinciarelli, G, 2005) |
| " This paper reports our study of the pharmacokinetics of mitomycin C (MMC) administered by intraperitoneal chemohyperthermic perfusion (ICHP) in patients with peritoneal carcinomatosis." | 5.11 | Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion. ( Cerretani, D; Cioppa, T; De Stefano, A; Giorgi, G; Marrelli, D; Nastri, G; Nencini, C; Pinto, E; Roviello, F; Urso, R, 2005) |
| "A prospective Phase II trial was carried out with 83 patients who had digestive tract cancer and peritoneal carcinomatosis to evaluate the tolerance and efficacy of IPCH with mitomycin C (MMC) associated with surgery." | 5.09 | Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. ( Beaujard, AC; Bienvenu, J; Caillot, JL; Francois, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Panteix, G; Vignal, J, 2000) |
| " 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin." | 5.09 | Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001) |
| "Adjuvant intraperitoneal therapy of gastric cancer by mitomycin bound to activated carbon particles is associated with an increased rate of postoperative complications." | 5.08 | Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. ( Czeijka, M; Holzberger, P; Jatzko, G; Lisborg, P; Neudorfer, H; Potrc, S; Rabl, H; Repse, S; Rosen, HR; Sandbichler, P; Zacherl, J, 1998) |
| "Mitomycin C-IPC after CRS was associated with better survival outcomes than CRS alone in patients with resectable peritoneal metastasis of colorectal cancer." | 4.31 | Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis. ( Baek, JH; Choi, GS; Kang, BW; Kim, CH; Kim, HJ; Kim, HR; Kim, JG; Kim, YJ; Park, JS; Park, SY, 2023) |
| " More than 50% of centers administer oxaliplatin (74%), or mitomycin-C (65%) in colorectal cancer; cisplatin in gastric cancer (73%) and mesothelioma (74%)." | 3.88 | Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey. ( Barrios, P; Cascales-Campos, P; Esteve-Pérez, N; Morales-Soriano, R; Segura-Sampedro, JJ, 2018) |
| "During heated intraperitoneal chemotherapy (HIPEC), neutropenia rates of 20 to 40% have been reported when mitomycin C (MMC) is dosed by weight or body surface area (BSA)." | 3.85 | Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C. ( Aycart, SN; Bhagwandin, S; Feferman, Y; Feingold, D; Kim, J; Labow, DM; Sarpel, U, 2017) |
| " Mitomycin C (MMC) is frequently used but not devoid of toxicity, of which the most common and feared is neutropenia." | 3.81 | Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy. ( Brigand, C; Brumaru, D; Kemmel, V; Lessinger, JM; Mercoli, HA; Meyer, N; Romain, B, 2015) |
| "Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)." | 3.80 | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014) |
| "Although peritoneal carcinomatosis (PC) from colorectal and appendiceal tumors is consistent with metastatic disease, complete cytoreduction with hyperthermic intraperitoneal chemotherapy (HIPEC) using mitomycin C (MMC) can improve survival." | 3.79 | A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. ( Ihemelandu, C; Levine, EA; Russell, G; Shen, P; Stewart, J; Votanopoulos, K, 2013) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 3.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "Patients undergoing cytoreductive surgery and perioperative hyperthermic chemotherapy (mitomycin C, intraoperatively; 5-fluorouracil early post-operatively) for peritoneal carcinomatosis from colorectal cancer from 1996 to 2003 were evaluated retrospectively." | 3.73 | Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. ( Ceranic, MS; Kecmanovic, DM; Kovacevic, PA; Pavlov, MJ; Sepetkovski, AV; Stamenkovic, AB, 2005) |
| "Cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis is used as a palliative treatment for a variety of malignancies." | 3.72 | Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. ( Fleming, RA; Lehman, AB; Levine, EA; Loggie, BW; McQuellon, RP; Russell, GB; Shen, P, 2003) |
| "We performed a retrospective chart review of a prospective database for patients undergoing CS and IPHC with mitomycin C for peritoneal carcinomatosis from colorectal primary lesions between December 1991 and April 2002." | 3.72 | Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. ( Fleming, RA; Geisinger, KR; Hawksworth, J; Levine, EA; Loggie, BW; Lovato, J; Shen, P, 2004) |
| "Activated carbon particles adsorbing mitomycin C (MMC-CH) was administered to four patients with peritoneal carcinomatosis of gastric cancer into their abdominal cavities." | 3.72 | [Intraperitoneal chemotherapy against peritoneal carcinomatosis of gastric cancer with activated carbon particles adsorbing mitomycin C for four patients]. ( Chou, H; Fujita, Y; Hagiwara, A; Kawakami, S; Ohgaki, M; Shiomi, A; Takashina, K; Takenaka, A; Yamagishi, H, 2004) |
| "Direct intraperitoneal chemotherapy with cisplatin or mitomycin prevents peritoneal carcinomatosis in experimental investigations." | 3.71 | Prophylaxis of peritoneal carcinomatosis in experimental investigations. ( Boltze, C; Halangk, W; Hribaschek, A; Kuhn, R; Lippert, H; Pross, M; Ridwelski, K, 2001) |
| "To apply (HIPEC) using mitomycin in patients with peritoneal carcinomatosis." | 3.70 | [Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute]. ( Beijnen, JH; Boot, H; Kaag, MM; van der Vange, N; Witkamp, AJ; Zoetmulder, FA, 1999) |
| "Intraperitoneal chemo-hyperthermia with mitomycin C was used to treat 28 patients with far advanced digestive adenocarcinoma and histologically confirmed peritoneal carcinomatosis." | 3.69 | Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. ( Banssillon, V; Bienvenu, J; Brachet, A; Burgard, G; Carry, PY; Gilly, FN; Guibert, B; Panteix, G; Salle, B; Sayag, AC, 1994) |
| " Adenocarcinoma patients receive mitomycin C and 5-fluorouracil; sarcoma patients receive cisplatin and doxorubicin." | 3.69 | Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. ( Sugarbaker, PH, 1994) |
| " hyperthermic perfusion (IPHP) with mitomycin C (MMC) for treating recurrent colorectal cancer." | 3.69 | Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. ( Arnold, MW; Dumond, D; Martin, EW; Schneebaum, S; Staubus, A; Young, DC, 1996) |
| "Based on a few previous studies, intra-peritoneal hyperthermic perfusion (IPHP) with Mitomycin C could become a beneficial treatment for peritoneal carcinomatosis." | 3.69 | [Study of the toxicity and results of intraperitoneal hyperthermic chemotherapy in 28 patients with peritoneal carcinomatosis]. ( Arnould, P; Bertrand, C; de Neve de Roden, A; Delvaux, P; Lechien, X; Mansvelt, B; Nockerman, P, 1997) |
| "The authors report the first results using intraperitoneal hyperthermic chemotherapy with mitomycin C or cisplatinum with protective hypothermia up to 32 degrees C in four cases of peritoneal carcinomatosis secondary to cancer of the ovary which was resistant to conventional treatment." | 3.68 | [Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data]. ( Brachet, A; Braillon, G; Carry, PY; Gilly, FN; Salle, B; Sayag, A, 1993) |
| "35 ovarian cancer patients with ascites have been treated intraperitoneally with mitomycin C or mitoxantrone or interferon beta or tumor necrosis factor (TNF)." | 3.68 | [Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms]. ( Chronides, A; Diedrich, K; Krebs, D; Mallmann, P; Wagner, U; Werner, A, 1991) |
| "Intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil has been used to rescue patients from peritoneal carcinomatosis after perforated cystadenocarcinoma of the large bowel or appendix." | 3.68 | Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. ( Jaffe, G; Landy, D; Pascal, R; Sugarbaker, PH, 1990) |
| "Survival of patients affected by colorectal cancer peritoneal metastases (CRC-PM) can be improved with combined complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)." | 3.11 | Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C. ( Brigand, C; Delhorme, JB; Diab, S; Liu, D; Rohr, S; Romain, B; Sauvinet, G; Séverac, F, 2022) |
| "Peritoneal carcinomatosis (PC) is a difficult clinical challenge in colorectal cancer (CRC) because conventional treatment modalities could not produce significant survival benefit, which highlights the acute need for new treatment strategies." | 2.79 | Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center. ( Huang, CQ; Li, Y; Liu, Y; Wu, HT; Yang, XJ; Yonemura, Y; Yu, Y, 2014) |
| "The median (range) peritoneal carcinomatosis index was 13 (3-20) requiring a median operative time of 6." | 2.78 | A phase I trial of thermal sensitization using induced oxidative stress in the context of HIPEC. ( Harrison, LE; Razavi, R; Tiesi, G; Wang, CC, 2013) |
| " Peritoneal and blood concentrations of cisplatinum were used to develop a pharmacokinetic model of the peritoneal and plasma compartments using NONMEM software." | 2.76 | Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure. ( Bakrin, N; Colomban, O; Cotte, E; Gilly, FN; Glehen, O; Guitton, J; Tod, M; Tranchand, B, 2011) |
| " The postoperative mortality rate was 0%; adverse events occurred in 18 (51%) patients." | 2.72 | Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. ( Greeno, E; Knutsen, A; Tuttle, TM; Zhang, Y, 2006) |
| "Patients with peritoneal carcinomatosis have a uniformly poor prognosis." | 2.71 | Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. ( Case, D; Fleming, R; Geisinger, KR; Hall, J; Levine, EA; Loggie, BW; McQuellon, R; Russell, G; Shen, P, 2003) |
| "To evaluate the tolerance of peritonectomy procedures (PP) combined with intraperitoneal chemohyperthermia (IPCH) in patients with peritoneal carcinomatosis (PC), a phase II study was carried out from January 1998 to September 2001." | 2.71 | Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. ( Beaujard, AC; Francois, Y; Freyer, G; Gilly, FN; Glehen, O; Guertsch, P; Mithieux, F; Osinsky, D; Panteix, G; Peyrat, P; Vignal, J, 2003) |
| "A retrospective study of 46 patients treated for peritoneal carcinomatosis from colon adenocarcinoma was performed." | 2.71 | Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. ( Campana, L; Foletto, M; Lise, M; Mocellin, S; Nitti, D; Pilati, P; Rossi, CR, 2003) |
| "Peritoneal carcinomatosis of colorectal cancer is probably best treated by cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC)." | 2.71 | Long-term survival of peritoneal carcinomatosis of colorectal origin. ( Boot, H; van Ruth, S; van Slooten, G; Verwaal, VJ; Witkamp, A; Zoetmulder, FA, 2005) |
| "Forty-two gastric cancer patients at T(3)II-T(4)III( B) stages and 96 patients with colorectal cancer at B to D stages admitted from January 1996 to October 1998 were randomly divided into control group (group I, 65 cases) receiving intraperitoneal thermochemotherapy, and group II (73 cases) receiving both intraperitoneal thermochemotherapy and intraperitoneal IL-2 immunotherapy." | 2.70 | Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. ( Fu, QG; Guo, RX; Meng, FD; Shen, XD, 2002) |
| "A total 124 patients with advanced gastric cancer were enrolled in this study." | 2.70 | [Effectiveness of continuous hyperthermic peritoneal perfusion for the peritoneal dissemination of gastric cancer]. ( Akiyama, H; Kunisaki, C; Matsuda, G; Nomura, M; Ono, H; Otsuka, Y; Shimada, H, 2002) |
| " In the present study, local injection of mitomycin C bound to activated carbon (M-CH) combined with i." | 2.70 | Local injection of M-CH combined with i.p. hyperthermic hypo-osmolar infusion is an effective therapy in advanced gastric cancer. ( Fan, Y; Hagiwara, A; Huang, Y; Ma, D; Qi, X; Su, G; Wang, W, 2002) |
| "Thirty-two patients with advanced gastric cancer underwent continuous hyperthermic peritoneal perfusion (CHPP) combined with surgery: to prevent peritoneal recurrence in 15 patients without peritoneal metastasis (prophylactic CHPP) and to treat 17 patients with peritoneal metastases (therapeutic CHPP)." | 2.69 | Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. ( Hirose, K; Iida, A; Katayama, K; Kusaka, Y; Nakagawara, G; Umeda, S; Yamaguchi, A, 1999) |
| "IPHP appears to be an effective treatment for peritoneal carcinomatosis." | 2.69 | [Peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemohyperthermia]. ( Balique, JG; Porcheron, J; Rey, Y; Szafnicki, K; Talabard, JN, 2000) |
| "Of 104 patients with peritoneal carcinomatosis from colon or rectal adenocarcinoma, five patients (4." | 2.69 | Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. ( Pestieau, SR; Sugarbaker, PH, 2000) |
| "There were 51 patients with colorectal cancer and 130 patients with appendiceal cancer." | 2.68 | Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Jablonski, KA; Sugarbaker, PH, 1995) |
| "Bibasilar atelectasis and pleural effusions are common findings after IPHC with MMC, but most of them do not necessarily warrant intervention." | 2.68 | Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. ( Chen, MY; Chiles, C; Choplin, RH; Fleming, RA; Loggie, BW; Perini, MA, 1997) |
| " The half-life in the peritoneal fluid (t1/2p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5-fluorouracil and mitomycin C (t1/2p, 1." | 2.67 | Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. ( Hasegawa, M; Hasegawa, T; Ito, A; Kuzuya, T; Nabeshima, T; Yamauchi, M, 1994) |
| "A new drug dosage form comprising activated carbon particles absorbing mitomycin C (MMC-CH) has the advantage of being retained in the peritoneal cavity and distributes a larger amount of mitomycin C for a long time." | 2.67 | [The prevention of peritoneal dissemination of gastric cancer with intraperitoneal activated carbon particles absorbing mitomycin C]. ( Chohei, S; Hagiwara, A; Imanishi, T; Ohgaki, M; Ohyama, T; Ozaki, K; Shimotsuma, M; Takahashi, T; Tsujimoto, H, 1994) |
| "For 15 patients with refractory gastric cancer and peritoneal metastasis, intraperitoneal hyperthermic perfusion (IPHP) using mitomycin C combined with extensive surgery was prescribed." | 2.67 | Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin C for patients with gastric cancer with peritoneal metastasis. ( Fujimoto, S; Kobayashi, K; Kure, M; Mutoh, T; Nagano, K; Ohkubo, H; Takahashi, M, 1992) |
| "Mucinous appendiceal neoplasms (MANs) are rare tumours and the primary cause of pseudomyxoma peritonei." | 2.66 | Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review. ( Alshahrani, MS; Lansom, J; Morris, DL; Soucisse, ML, 2020) |
| "A new drug dosage form comprising activated carbon particles adsorbing mitomycin C (MMC-CH) is designed to slowly release its components, and has affinity for the tumor surface and lymph nodes and a tendency to stay long in the local portion." | 2.66 | Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Clinical trials. ( Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T, 1987) |
| "Management of peritoneal disease from appendiceal neoplasms has historically been with debulking surgery." | 2.61 | Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms. ( Craig Lynch, A; Heriot, A; Michael, M; Narasimhan, V; Pham, T; Ramsay, R; Tie, J; Warrier, S, 2019) |
| " Despite its pharmacokinetic advantages, the aortic stop flow technique is currently not recommendable for routine use." | 2.43 | Pharmacokinetics of the antineoplastic drug mitomycin C in regional chemotherapy using the aortic stop flow technique in advanced pancreatic carcinoma. ( Gebauer, T; Grote, R; Lippert, H; Martens-Lobenhoffer, J; Meyer, F; Ridwelski, K, 2005) |
| "Because patients with advanced gastric cancers have less than 50% chance of cure after R0 resection, the need for an adjuvant treatment to eradicate residual microscopic disease is clear." | 2.43 | A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy. ( Yu, W, 2006) |
| " Our data indicate that dosing based on body surface area is rational and reliable." | 2.42 | Pharmacokinetics of intraperitoneal mitomycin C. ( van Ruth, S; Verwaal, VJ; Zoetmulder, FA, 2003) |
| "Peritoneal carcinomatosis is a common manifestation of digestive-tract cancer and has been regarded a terminal disease with a short median survival." | 2.42 | Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. ( Gilly, FN; Glehen, O; Mohamed, F, 2004) |
| "The recurrence rate of resected gastric cancer with curative intent was around 20%." | 2.40 | [Treatment of recurrent gastric cancer]. ( Sakata, Y; Tsushima, K, 1998) |
| "Adverse events after HIPEC were estimated by common terminology criteria for adverse events version 5." | 1.91 | Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching A ( Guo, X; Li, Y; Lin, Y; Lv, J; Ruan, T; Shen, C; Tao, K; Wu, C; Xiang, F; Zeng, X, 2023) |
| "A total of 124 colorectal cancer patients who underwent CRS with HIPEC between March 2015 and January 2019 were evaluated." | 1.72 | Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis. ( Baik, SH; Jeon, Y; Kang, J; Lee, HW; Lee, SJ; Park, EJ, 2022) |
| "Patients with metastatic colorectal cancer (mCRC) carrying BRAF (mutBRAF) or KRAS mutation (mutKRAS) have an inferior prognosis after liver or lung surgery, whereas the prognostic role in the context of peritoneal metastasis (PM) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been less investigated." | 1.72 | Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. ( Dagenborg, VJ; Dueland, S; Flatmark, K; Goscinski, MA; Hofsli, E; Larsen, SG; Lund-Iversen, M; Sorbye, H; Steigen, SE; Torgunrud, A, 2022) |
| "Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis." | 1.62 | Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO ( Abatini, C; Attalla El Halabieh, M; Di Giorgio, A; Lodoli, C; Pacelli, F; Rotolo, S; Santullo, F, 2021) |
| " Because MMC is the preferred agent of choice used in CRS-HIPEC, future studies should investigate optimal MMC dosing and patient selection when splenectomy is performed to balance survival benefit with hematologic toxicities." | 1.62 | Pancytopenia after administration of hyperthermic intraperitoneal chemotherapy with mitomycin-C: local therapy and systemic toxicity. ( Chung, SY; Saif, MW; Shen, J; Wu, V, 2021) |
| "CRS/HIPEC performed is a safe method with low perioperative mortality." | 1.56 | Evaluation and management of toxicity of cytoreductive surgery/hyperthermic intraperitoneal chemotherapy: the initial experience of a single centre study. ( Flasarova, D; Havlik, R; Klos, D; Lemstrova, R; Lovecek, M; Melichar, B; Mohelnikova-Duchonova, B; Neoral, C; Spisarova, M, 2020) |
| "Mitomycin-C (MMC) was used in 20% and oxaliplatin in 10%." | 1.56 | Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. ( Ashwin, KR; Kumar C, R; Rauthan, A; Somashekhar, SP; Yethadka, R; Zaveri, S, 2020) |
| " The study is to analyze the incidence of perioperative serious adverse events (SAEs) of CRS + HIPEC to treat PMP patients, and identify the risk factors, for guiding the prevention of SAEs." | 1.56 | Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center. ( Chen, LF; Ji, ZH; Li, XB; Li, Y; Lin, YL; Ma, R; Yan, FC; Yang, ZR; Zhang, J, 2020) |
| "Pseudomyxoma peritonei is rare, almost always of appendiceal origin, and presents in various ways relevant to abdominal surgeons." | 1.56 | Mode of Presentation in 1070 Patients With Perforated Epithelial Appendiceal Tumors, Predominantly with Pseudomyxoma Peritonei. ( Cecil, TD; Chandrakumaran, K; Dayal, S; Mohamed, F; Moran, BJ; Shariff, US, 2020) |
| " An increasing dosage of TN (from 0." | 1.51 | Comparing the cytotoxicity of taurolidine, mitomycin C, and oxaliplatin on the proliferation of in vitro colon carcinoma cells following pressurized intra-peritoneal aerosol chemotherapy (PIPAC). ( Arafkas, M; Chaudhry, H; Khosrawipour, T; Khosrawipour, V; Knoefel, WT; Pigazzi, A; Schubert, J, 2019) |
| "Colorectal peritoneal carcinomatosis (PC) is commonly treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)." | 1.48 | Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. ( Aalbers, AGJ; Boot, H; Huitema, ADR; Kok, NFM; van Eden, WJ; Woensdregt, K, 2018) |
| "Compare long-term outcomes in colorectal cancer (CRC) patients with peritoneal carcinomatosis (PC) treated with peritonectomy/HIPEC using oxaliplatin versus MMC." | 1.46 | Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. ( Huo, YR; Leung, V; Liauw, W; Morris, DL, 2017) |
| "Pseudomyxoma peritonei is a disease that results from a perforated mucinous neoplasm of the appendix so that mucinous ascites and mucin-producing tumor cells are widely disseminated in a characteristic pattern throughout the abdomen and pelvis." | 1.46 | Management of an inguinal hernia in patients with pseudomyxoma peritonei. ( Sugarbaker, PH, 2017) |
| "Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades." | 1.46 | Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC. ( Abel, ML; Blazer, DG; Kokosis, G, 2017) |
| "Weight loss was common after HIPEC as 38 of 41 patients demonstrated weight loss." | 1.43 | Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates. ( Beaty, KA; Dineen, SP; Fournier, KF; Mansfield, PF; Rafeeq, S; Robinson, KA; Roland, CL; Royal, RE, 2016) |
| "The aim of this study was to assess the risk of HCs after CRS combined with HIPEC-Ox versus other drugs, and to determine predictive factors for HCs after HIPEC-Ox." | 1.43 | Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors. ( Charrier, T; Cotte, E; Elias, D; Eveno, C; Glehen, O; Gocevska, S; Goere, D; Maurice, C; Ortega-Deballon, P; Passot, G; Peron, J; Pocard, M; Quénet, F; Vaudoyer, D, 2016) |
| " This study evaluated the efficacy and safety of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of PPSC." | 1.43 | Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study. ( Ji, ZH; Li, Y; Peng, KW; Sun, JH; Wu, HT; Yonemura, Y; Zhang, Q, 2016) |
| "Conclusions Prophylactic HIPEC for appendiceal neoplasms is feasible, safe and may be performed laparoscopically." | 1.43 | Prophylactic hyperthermic intraperitoneal chemotherapy in patients with epithelial appendiceal neoplasms. ( Aycart, SN; Berger, Y; Hiotis, S; Labow, DM; Sarpel, U; Shtilbans, T; Tuvin, D, 2016) |
| "Pseudomyxoma peritonei was the primary indication, and a glissonectomy was more frequently performed for patients with high peritoneal cancer index." | 1.43 | Digital Glissonectomy: A Safe Perihepatic Peritonectomy. ( Bakrin, N; Bonnefoy, I; Cotte, E; Glehen, O; Kepenekian, V; Kim, BJ; Passot, G; Vaudoyer, D, 2016) |
| "In Taiwan, colorectal cancer with peritoneal carcinomatosis is considered a terminal condition." | 1.43 | Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis. ( Chen, CH; Hsieh, MC; Lin, EK; Lu, YJ; Wu, SY, 2016) |
| "In patients undergoing colorectal cancer surgery, skeletal muscle depletion (sarcopenia) is associated with impaired postoperative recovery and decreased survival." | 1.42 | Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer. ( Boerma, D; Bollen, TL; Braam, HJ; de Hingh, IH; van Oudheusden, TR; van Ramshorst, B; van Vugt, JL; Vestering, A; Wiezer, MJ, 2015) |
| "The purpose of this study is to evaluate the fluctuations of coagulation parameters during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) and confirm beyond doubt that epidural anaesthesia is safe with this type of operations." | 1.42 | Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option. ( Alevizos, L; Daskalou, T; Eleftheriadis, S; Iatrou, C; Korakianitis, O; Mavroudis, C; Stamou, K; Tentes, AA; Vogiatzaki, T, 2015) |
| "Ovarian cancer was transplanted i." | 1.42 | [Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer]. ( Alexandrov, VA; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Kireeva, GS; Kopteva, OS; Krasilnikova, LA; Maidin, MA; Semenov, AL; Stukov, AN; Vasilieva, IN; Vyshinskaya, EA, 2015) |
| "To treat carcinomatosis, we use cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC)." | 1.40 | Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. ( Levine, EA; Loggie, BL; Russell, GB; Shen, P; Stewart, JH; Votanopoulos, KI, 2014) |
| "Mitomycin C (88." | 1.40 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. ( Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ, 2014) |
| "Long-term OS after CRS and HIPEC for colorectal cancer is associated with CC and neoadjuvant therapy containing bevacizumab." | 1.40 | Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. ( Ceelen, W; Pattyn, P; Putte, DV; Van Nieuwenhove, Y, 2014) |
| "Most classifications of mucinous appendiceal neoplasms (MAN) do not take into consideration the type of primary tumor or the burden of peritoneal disease." | 1.40 | Evaluation of a new staging classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 229 patients with mucinous appendiceal neoplasms with or without peritoneal dissemination. ( Esquivel, J; Garcia, SS; Hicken, W; Seibel, J; Shekitka, K; Trout, R, 2014) |
| "Treatment of peritoneal carcinomatosis (PC) of colorectal cancer (CRC) origin is relatively ineffective and associated with morbidity." | 1.40 | Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis. ( Bemelman, WA; Buskens, CJ; Crezee, J; Gardenbroek, TJ; Punt, CJ; Sloothaak, DA; Tanis, PJ, 2014) |
| "Among the CRC and appendiceal cancer group the median overall survival was 20." | 1.40 | [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin]. ( Aderka, D; Berger, Y; Brenner, B; Golan, T; Gutman, M; Lebedyev, A; Levi, Y; Natur, M; Nevler, A; Purim, O; Zbar, AP, 2014) |
| "Patients with PC from colorectal or appendiceal cancer, pseudomyxoma peritonei or malignant peritoneal mesothelioma referred to the single national HIPEC centre were prospectively registered from June 2006 to July 2012." | 1.39 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience. ( Hagemann-Madsen, R; Iversen, LH; Laurberg, S; Rasmussen, PC, 2013) |
| "Severe obesity is associated with decreased long-term survival only in patients with LGA primary disease; however, application of CRS/HIPEC still offers meaningful prolongation of life." | 1.39 | Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. ( Levine, EA; Randle, RW; Shen, P; Stewart, JH; Swett, KR; Swords, DS; Votanopoulos, KI, 2013) |
| "Pseudomyxoma peritonei and peritoneal carcinomatosis derived from appendiceal epithelial tumors are controversial entities from classification to treatment." | 1.39 | Controversy and consensus on the management of patients with pseudomyxoma peritonei. ( Faris, JE; Ryan, DP, 2013) |
| "Pseudomyxoma peritonei is a diffuse peritoneal malignancy that generally originates form a perforated appendiceal tumor." | 1.39 | Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. ( Cecil, TD; Chandrakumaran, K; Dayal, S; Mohamed, F; Moran, BJ; Riss, S; Taflampas, P, 2013) |
| "Surgical cytoreduction of peritoneal surface malignancy of colorectal origin in combination with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) has become an established treatment approach." | 1.36 | Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model. ( Atanassow, V; Braumann, C; Caldenas, S; Hartmann, J; Kilian, M; Makareinis, A; Raue, W; Schwenk, W, 2010) |
| "In patients with colorectal cancer peritoneal carcinomatosis (CRPC), only patients with a complete cytoreduction will benefit." | 1.36 | Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. ( Chua, TC; Esquivel, J; Morris, DL, 2010) |
| "A case of hepatocellular carcinoma, successfully treated with multimodal loco-regional treatments, is reported." | 1.36 | [Successful treatment of multiple pulmonary and peritoneal recurrence of hepatocellular carcinoma with bronchial artery infusion therapy and PEIT followed by surgery--a case report]. ( Akiyama, H; Amikura, K; Kawashima, Y; Nakajima, T; Nishimura, Y; Sakamoto, H; Tanaka, Y; Yamagata, Y; Yamaura, T; Yatsuoka, T; Yokoyama, Y, 2010) |
| "We conclude that minimal residual disease, compared with macroscopically complete cytoreduction, correlated to failure in critical anatomical areas, suggesting the need for maximal cytoreductive surgical efforts." | 1.35 | Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). ( Baratti, D; Cabras, AD; Deraco, M; Dileo, P; Kusamura, S; Laterza, B, 2009) |
| " The dose-response relationships for melphalan and irinotecan in individual samples showed great variability." | 1.35 | Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis. ( Glimelius, B; Graf, W; Grundmark, B; Larsson, R; Mahteme, H; Nygren, P; Påhlman, L; Tholander, B; von Heideman, A, 2008) |
| "7 % and adverse events were bone marrow suppression, 13; nephrotoxicity, 14; neutropenic infection, 2 and pulmonary toxicity, 1." | 1.34 | Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. ( Baratti, D; Costanzo, P; Deraco, M; Favaro, M; Gavazzi, C; Grosso, F; Kusamura, S; Laterza, B; Oliva, GD; Younan, R, 2007) |
| " Performing splenectomy and CDDP dosage for HIPEC >240 mg were proven to be independent risk factors for both G3-4 hyperamylasemia and POPF." | 1.34 | Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( Antonucci, A; Baratti, D; Deraco, M; Gavazzi, C; Kusamura, S; Laterza, B; Oliva, GD; Younan, R, 2007) |
| "Pseudomyxoma peritonei is a rare disease." | 1.33 | Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. ( Bossard, N; Brigand, C; Causeret, S; Faheez, M; Gilly, F; Glehen, O; Loungnarath, R; Sayag-Beaujard, AC, 2005) |
| "Forty-eight patients with peritoneal surface malignancy were treated with hyperthermic intraperitoneal mitomycin C chemotherapy after a complete cytoreduction to remove all visible evidence of mucinous tumor." | 1.33 | Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. ( Carmignani, CP; Stuart, OA; Sugarbaker, PH, 2006) |
| "A total of 104 patients with primary gastric cancer with peritoneal dissemination were enrolled in this study." | 1.33 | [Effectiveness of intraperitoneal chemotherapy using new-aged drugs for the peritoneal dissemination of gastric cancer]. ( Fujimura, T; Fujita, H; Fushida, S; Kinami, S; Ninomiya, I; Nishimura, G; Ohta, T, 2005) |
| "Paclitaxel was ineffective, and so we opted for weekly administration of low-dose CDDP combined with TS-1, which led to the third recovery." | 1.33 | [A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs]. ( Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y, 2006) |
| "Peritoneal mesothelioma is a rare disease with few therapeutic options." | 1.33 | Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. ( Brigand, C; Gilly, FN; Glehen, O; Isaac, S; Mohamed, F; Monneuse, O; Sayag-Beaujard, AC, 2006) |
| "Prognosis was poorer for patients with colon cancer, who had a median survival of 7." | 1.32 | Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer. ( Karakozis, S; Stamou, KM; Sugarbaker, PH, 2003) |
| "Peritoneal carcinomatosis has been regarded as a lethal clinical entity." | 1.32 | Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. ( Cotte, E; François, Y; Freyer, G; Gilly, FN; Glehen, O; Isaac, S; Kwiatkowski, F; Osinsky, D; Sayag-Beaujard, AC; Trillet-Lenoir, V; Vignal, J, 2003) |
| "In advanced gastric cancer, peritoneal recurrence is the main cause of death after curative surgical resection." | 1.32 | Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative chemotherapy in advanced gastric carcinoma. ( Azama, T; Fujiwara, Y; Ishii, T; Monden, M; Mori, T; Sugita, Y; Takiguchi, S; Taniguchi, K; Yamazaki, K; Yano, M; Yasuda, T, 2004) |
| " As cytostatics for hyperthermic peritoneal perfusion, we have used Mitomycin in a dosage of 18 mg/m2 plus Melphalan in a dosage of 25 mg/m2." | 1.32 | Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases. ( Müller, H; Nakchbandi, V, 2004) |
| "Colorectal cancer with peritoneal carcinomatosis is usually considered incurable." | 1.32 | Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. ( Cotte, E; Gilly, FN; Glehen, O; Sayag-Beaujard, AC; Schreiber, V; Vignal, J, 2004) |
| "Mitomycin and cisplatin were highly effective to prevent peritoneal carcinomatosis (direct application immediately after tumor cell transfer - 1 (st) treatment group)." | 1.32 | [Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis]. ( Fenske, A; Hribaschek, A; Krüger, S; Lippert, H; Meyer, F; Pross, M; Ridwelski, K, 2004) |
| "Treatment of advanced gastric cancers with peritonitis carcinomatosa is very difficult, because none of the various therapies (operation, chemotherapy, hyperthermia etc." | 1.32 | [A case of advanced gastric cancer with peritonitis carcinomatosa resected with intraperitoneal chemotherapy based on chemosensitivity test with ascites]. ( Doi, K; Horiuchi, T; Nakamura, T; Okubo, Y; Shimada, K; Tanabe, S; Tanaka, K; Tanaka, S; Uchinami, M; Yoshida, M, 2004) |
| "Mitomycin C was administered as a perfusate at 10 mg/l." | 1.32 | Treatment of peritoneal carcinomatosis in patients with digestive cancers with combination of intraperitoneal hyperthermia and mitomycin C. ( Banssillon, V; Bienvenu, J; Francois, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Panteix, G; Sadeghi-Looyeh, B; Sayag-Beaujard, AC; Vignal, J, 2004) |
| "The prognosis for intraabdominal carcinomatosis is poor with conventional treatments and modalities." | 1.31 | Intraoperative modality of treatment for peritoneal carcinomatosis: use of hyperthermic interperitoneal chemoperfusion. ( Chase, VA; Hunley, EK; Kuhn, JA; Loggie, BW; McCarty, TM; Sutton, SW; Yancey, LW, 2002) |
| "Lymph node metastasis was not present." | 1.31 | [Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report]. ( Iesato, H; Morishita, Y; Nakagami, K; Ohwada, S; Ohya, T; Sasaki, T; Sugitani, K; Takahashi, T; Yokomori, T, 2000) |
| "5-Fluorouracil and cisplatin were administered intraperitoneally on postoperative days 1-4, and this was repeated at 4-week intervals." | 1.31 | Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. ( Chung, HC; Min, JS; Noh, SH; Roh, JK; Shin, DW; Yoo, CH, 2001) |
| "Diffuse pyogenic gelatinous ascites and a large cystic mass with a grayish wall, and a hard solid lesion in part were found." | 1.31 | Disseminated peritoneal adenomucinosis associated with a panperitonitis-like onset: report of a case. ( Kuroki, Y; Otagiri, S; Tsukada, K, 2001) |
| "The outcome of patients with mucinous appendiceal neoplasms with peritoneal surface dissemination has changed as a result of a better understanding of the clinical and pathologic features of this disease." | 1.31 | Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. ( Esquivel, J; Sugarbaker, PH, 2001) |
| "We report three patients with recurrent gastric cancer responding to TS-1 therapy after combination chemotherapy with 5-fluorouracil, mitomycin C and cisplatin." | 1.31 | [Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin]. ( Hayashi, K; Iijima, S; Koyama, Y; Miyazawa, K; Morikawa, A; Murakami, M; Okabe, R; Ozaki, K; Sugiyama, A; Suzuki, A, 2002) |
| "IHCP combined with aggressive surgery was performed in 48 gastric carcinoma patients with peritoneal carcinomatosis; 18 gastric carcinoma patients with peritoneal carcinomatosis serving as controls were treated with surgery alone." | 1.30 | Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. ( Fujimoto, S; Isawa, E; Kobayashi, K; Mutou, T; Ohkubo, H; Sumida, M; Takahashi, M; Toyosawa, T, 1997) |
| "We report 42 cases of gastric cancer with peritoneal carcinosis treated with intraperitoneal chemohyperthermia." | 1.30 | [Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis]. ( Bienvenu, J; François, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Peyrat, PP; Sadeghi-Looyeh, B; Sayag-Beaujard, AC; Vignal, J, 1997) |
| "The role in colorectal cancer is less clear, although there are some reports that suggest a benefit." | 1.30 | Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. ( Clingan, P; Horsell, KW; King, DW; Merten, S; Morris, DL, 1999) |
| "Six patients with gastric cancer and two patients with colon cancer underwent these procedures." | 1.29 | [Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer]. ( Fujimura, T; Fujita, H; Fushida, S; Hirono, Y; Itoh, H; Kaji, M; Kinami, S; Nakagawara, H; Nakai, M; Yonemura, Y, 1995) |
| " The dosage was 14 mg/m2 (7 mg/m2 at second and following administrations) of MMC and 35 mg/m2 of CDDP and they were repeatedly administered in the abdominal cavity via the drug delivery system." | 1.29 | [Intraperitoneal repeated chemotherapy using CDDP combined with MMC for carcinomatous peritonitis]. ( Arai, K; Kitamura, M; Miyashita, K, 1993) |
| "A new dosage format (MMC-CH) of mitomycin C, which is composed of mitomycin C on activated carbon particles, was efficacious for prevention of peritoneal recurrence of gastric cancer." | 1.29 | [Four long-surviving cases of gastric cancer with peritoneal dissemination treated by intraperitoneal administration of mitomycin C adsorbed on activated carbon particles]. ( Hagiwara, A; Oyama, T; Ozaki, K; Sakakibara, T; Sakakura, C; Sasaki, S; Shimotsuma, M; Takahashi, T; Tsujimoto, H, 1993) |
| "There were 43 colorectal and 104 appendiceal cancer patients." | 1.29 | Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Chang, D; Koslowe, P; Sugarbaker, PH, 1996) |
| " The method was found to be safe when flow was observed and dosage decisions were made during perfusion according to flow." | 1.29 | Peritoneal carcinomatosis and radioimmunoguided surgery. ( Arnold, MW; Martin, EW; Schneebaum, S; Staubus, AE, 1996) |
| "Peritoneal carcinomatosis has been regarded as a uniformly lethal clinical entity with no specific plan for management." | 1.29 | Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. ( Sugarbaker, PH, 1996) |
| "Pseudomyxoma peritonei is a rare disease caused by a perforated adenoma of the appendix." | 1.29 | Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. ( Sugarbaker, PH; Zoetmulder, FA, 1996) |
| " A marked pharmacokinetic advantage was observed when 5-FU and CDDP were administered." | 1.28 | [Large volume intraperitoneal chemotherapy as treatment for the peritoneal carcinomatosis from gastric cancer]. ( Ito, A; Ito, K; Kodera, Y; Kondo, K; Kuzuya, T; Nagai, S; Nakahara, H; Satta, T; Takagi, H; Yamauchi, M, 1992) |
| "The subjects were 41 cases of gastric cancer with peritoneal dissemination but without hepatic metastasis, which we have experienced in the past 7 years." | 1.28 | [Treatment of gastric cancer patients with peritoneal metastasis by continuous hyperthermic peritoneal infusion with mitomycin C and cisplatin]. ( Fujimura, T; Kamata, T; Katayama, K; Kimura, H; Matsuki, N; Ohoyama, S; Sakuma, H; Sawa, T; Takekawa, S; Yonemura, Y, 1991) |
| "A total of 31 patients with gastric cancer showing peritoneal dissemination received continuous hyperthermic peritoneal perfusion (CHPP) in combination with the administration of cisplatin (CDDP) and mitomycin C (MMC)." | 1.28 | Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. ( Fujimura, T; Fushida, S; Hasegawa, H; Kamata, T; Katayama, K; Miwa, K; Sugiyama, K; Takegawa, S; Urade, M; Yonemura, Y, 1990) |
| "Six patients with peritoneal recurrence after radical operation for gastric cancer were treated by an intraperitoneal hyperthermic perfusion (IPHP) combined with surgery (IPHP group)." | 1.28 | [Clinical results of intraperitoneal hyperthermic perfusion combined with surgery in patients with peritoneal recurrence from gastric cancer]. ( Fujimoto, S; Kiuchi, S; Kobayashi, K; Kokubun, M; Konno, C; Okui, K; Shrestha, RD, 1990) |
| "Some 74 of 469 patients of gastric cancer, who underwent surgical treatment over the last 7 years in our department, had peritoneal dissemination and 24 of them were treated with the drugs described above." | 1.28 | [Intraoperative intraperitoneal administration of mitomycin C and OK-432 for peritoneal dissemination of gastric cancer]. ( Azuma, S; Furuta, T; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tanemura, H; Yoshida, A, 1990) |
| "5-Fluorouracil was given on postoperative days 2-5 at 15 and 20 mg/kg, respectively." | 1.28 | Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. ( Cunliffe, WJ; DeBruijn, EA; Graves, T; Hull, WE; Mullins, RE; Oliff, L; Schlag, P; Sugarbaker, PH, 1990) |
| "For prevention and therapy of peritoneal dissemination, a new dosage from (MMC-CH) comprising carbon particles adsorbing mitomycin C was given to 44 patients (the MMC-CH group) undergoing gastrectomy for gastric cancer, of which advancing stage was classified into the category of H0, and S2 or S3, and P0, P1, P2 or P3 according to the General Rules for the Gastric Cancer Study." | 1.28 | [Intraoperative chemotherapy against peritoneal dissemination of gastric cancer with intraperitoneal activated carbon particles adsorbing mitomycin C]. ( Hagiwara, A; Iwamoto, A; Sawai, K; Takahashi, T; Yamaguchi, T; Yoneyama, C, 1989) |
| "Nineteen far-advanced gastric cancer patients, including peritoneal dissemination, underwent surgical treatment followed by intraperitoneal hyperthermic perfusion (IPHP)." | 1.28 | [Clinical evaluation of intraperitoneal hyperthermic perfusion in far-advanced gastric cancer]. ( Fujimoto, S; Kiuchi, S; Kobayashi, K; Kokubun, M; Konno, C; Okui, K; Shrestha, RD; Takahashi, M, 1989) |
| "A new form of dosage (MMC-CH) was composed of activated carbon particles adsorbing mitomycin C." | 1.28 | [Intraoperative chemotherapy with intraperitoneal activated carbon particles adsorbing mitomycin C against peritoneal dissemination of gastric cancer]. ( Hagiwara, A; Itoh, M; Iwamoto, A; Kondoh, S; Sasabe, T; Seiki, K; Shimotsuma, M; Takahashi, T; Yamaguchi, T; Yoneyama, C, 1989) |
| "Thirty-four patients with advanced gastric cancers had received continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination (PD)." | 1.28 | [Continuous hyperthermic peritoneal perfusion with cisplatin and mitomycin C for peritoneal dissemination in gastric cancer]. ( Fujimura, T; Hasegawa, H; Hashimoto, T; Katayama, K; Matsuda, Y; Miyata, R; Sugiyama, K; Urade, M; Yamaguchi, A; Yonemura, Y, 1989) |
| " This extensive surgery combined with IPHP using MMC and MIS was well tolerated and is a safe antitumor treatment for gastric cancer with peritoneal dissemination." | 1.27 | Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. ( Arimizu, N; Fujimoto, S; Kiuchi, S; Kobayashi, K; Kokubun, M; Miyoshi, T; Ohta, M; Okui, K; Shrestha, RD; Takahashi, M, 1988) |
| "Persistent or recurrent peritoneal carcinomatosis (PC) documented at second-look surgery has proved relatively refractory to second-line therapy." | 1.27 | Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery. ( Alberts, DS; Graham, V; Monk, BJ; Surwit, EA, 1988) |
| "A new dosage form of activated carbon particles adsorbing mitomycin C (MMC-CH) was studied for its therapeutic effects on peritoneal dissemination in both animal experiments and preliminary clinical trials." | 1.27 | Intraoperative chemotherapy with carbon particles adsorbing mitomycin C for gastric cancer with peritoneal dissemination in rabbits. ( Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T, 1988) |
| "Fourteen patients with far-advanced gastric cancer were treated surgically followed by intraperitoneal hyperthermic perfusion (IPHP) with mitomycin C (MMC) and misonidazole (MIS), a thermosensitizing drug." | 1.27 | [Extended treatment for gastric cancer patients with peritoneal seeding]. ( Fujimoto, S; Kiuchi, S; Kobayashi, K; Kokubun, M; Ohta, M; Okui, K; Shrestha, RD, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (5.42) | 18.7374 |
| 1990's | 71 (17.49) | 18.2507 |
| 2000's | 134 (33.00) | 29.6817 |
| 2010's | 123 (30.30) | 24.3611 |
| 2020's | 56 (13.79) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, SJ | 3 |
| Jeon, Y | 1 |
| Lee, HW | 1 |
| Kang, J | 1 |
| Baik, SH | 2 |
| Park, EJ | 2 |
| Larsen, SG | 5 |
| Goscinski, MA | 1 |
| Dueland, S | 3 |
| Steigen, SE | 1 |
| Hofsli, E | 1 |
| Torgunrud, A | 1 |
| Lund-Iversen, M | 1 |
| Dagenborg, VJ | 1 |
| Flatmark, K | 5 |
| Sorbye, H | 1 |
| Fernando, D | 1 |
| Larach, JT | 1 |
| Flood, MP | 1 |
| Warrier, SK | 1 |
| McCormick, JJ | 1 |
| Heriot, AG | 1 |
| Waters, PS | 1 |
| Sugarbaker, PH | 40 |
| Baron, C | 1 |
| Buchholz, M | 1 |
| Majchrzak-Stiller, B | 1 |
| Peters, I | 1 |
| Fein, D | 1 |
| Müller, T | 1 |
| Uhl, W | 1 |
| Höhn, P | 1 |
| Strotmann, J | 1 |
| Braumann, C | 2 |
| Delhorme, JB | 3 |
| Sauvinet, G | 1 |
| Séverac, F | 1 |
| Diab, S | 1 |
| Liu, D | 1 |
| Rohr, S | 2 |
| Romain, B | 3 |
| Brigand, C | 5 |
| Nikiforchin, A | 4 |
| Sardi, A | 8 |
| King, MC | 4 |
| Baron, E | 4 |
| Lopez-Ramirez, F | 4 |
| Nieroda, C | 5 |
| Gushchin, V | 7 |
| Mangieri, CW | 2 |
| Valenzuela, CD | 2 |
| Solsky, IB | 2 |
| Erali, RA | 3 |
| Votanopoulos, KI | 6 |
| Shen, P | 15 |
| Levine, EA | 17 |
| Park, SY | 2 |
| Park, JS | 2 |
| Kim, HJ | 2 |
| Kim, JG | 2 |
| Kang, BW | 2 |
| Baek, JH | 2 |
| Kim, HR | 2 |
| Kim, CH | 2 |
| Kim, YJ | 2 |
| Choi, GS | 2 |
| Geva, R | 1 |
| Alon, G | 1 |
| Nathanson, M | 1 |
| Bar-David, S | 2 |
| Nevo, N | 2 |
| Aizic, A | 1 |
| Peles-Avraham, S | 1 |
| Lahat, G | 2 |
| Nizri, E | 2 |
| Lee Goldstein, A | 1 |
| Abu-Abeid, A | 1 |
| Dayan, D | 1 |
| Guo, X | 1 |
| Lin, Y | 1 |
| Shen, C | 1 |
| Li, Y | 7 |
| Xiang, F | 1 |
| Ruan, T | 1 |
| Zeng, X | 1 |
| Lv, J | 1 |
| Tao, K | 1 |
| Wu, C | 1 |
| Hassan, S | 1 |
| Dritsas, S | 1 |
| O'Dwyer, ST | 3 |
| Aziz, O | 2 |
| Sutton, P | 1 |
| Wang, X | 3 |
| Fish, R | 1 |
| Wintjens, AGWE | 1 |
| Liu, H | 1 |
| Fransen, PKH | 1 |
| Lenaerts, K | 1 |
| van Almen, GC | 1 |
| Gijbels, MJ | 1 |
| Hadfoune, M | 1 |
| Boonen, BTC | 1 |
| Lieuwes, NG | 1 |
| Biemans, R | 1 |
| Dubois, LJ | 1 |
| Dankers, PYW | 1 |
| de Hingh, IHJT | 6 |
| Bouvy, ND | 1 |
| Forsythe, SD | 1 |
| Edenhoffer, N | 1 |
| Meeker, W | 1 |
| Wajih, N | 1 |
| Schaaf, CR | 1 |
| Laney, P | 1 |
| Vanezuela, CD | 1 |
| Li, W | 1 |
| Soker, S | 1 |
| Ghelardi, F | 1 |
| Raimondi, A | 1 |
| Morano, F | 1 |
| Randon, G | 1 |
| Pannone, A | 1 |
| Guaglio, M | 3 |
| Mazzoli, G | 1 |
| Nasca, V | 1 |
| Milione, M | 1 |
| Leoncini, G | 1 |
| Sabella, G | 1 |
| Greco, GF | 1 |
| Lampis, BR | 1 |
| Galassi, M | 1 |
| Delfanti, S | 1 |
| Nannini, M | 1 |
| Intini, R | 1 |
| Baratti, D | 19 |
| Di Bartolomeo, M | 1 |
| Deraco, M | 22 |
| Pietrantonio, F | 1 |
| Hübner, M | 2 |
| van Der Speeten, K | 4 |
| Govaerts, K | 1 |
| de Hingh, I | 2 |
| Villeneuve, L | 1 |
| Kusamura, S | 20 |
| Glehen, O | 24 |
| Wisselink, DD | 1 |
| Braakhuis, LLF | 1 |
| Gallo, G | 1 |
| van Grevenstein, WMU | 3 |
| van Dieren, S | 1 |
| Kok, NFM | 4 |
| de Reuver, PR | 4 |
| Tanis, PJ | 4 |
| Lemstrova, R | 1 |
| Flasarova, D | 1 |
| Spisarova, M | 1 |
| Melichar, B | 1 |
| Lovecek, M | 1 |
| Havlik, R | 1 |
| Neoral, C | 1 |
| Mohelnikova-Duchonova, B | 1 |
| Klos, D | 1 |
| Koh, CE | 1 |
| Ansari, N | 1 |
| Morris, D | 2 |
| Moran, B | 6 |
| Sørensen, O | 1 |
| Andersen, AM | 1 |
| Giercksky, KE | 2 |
| Somashekhar, SP | 2 |
| Yethadka, R | 1 |
| Kumar C, R | 1 |
| Ashwin, KR | 1 |
| Zaveri, S | 1 |
| Rauthan, A | 1 |
| Azmi, N | 1 |
| Montenovo, M | 2 |
| Moaven, O | 1 |
| Mansfield, P | 3 |
| Bartlett, DL | 5 |
| Russell, G | 4 |
| McQuellon, R | 2 |
| Stewart, JH | 9 |
| Narasimhan, V | 2 |
| Warrier, S | 2 |
| Michael, M | 2 |
| Ramsay, R | 2 |
| Heriot, A | 2 |
| Lu, PW | 1 |
| Fields, AC | 1 |
| Shabat, G | 1 |
| Bleday, R | 1 |
| Goldberg, JE | 1 |
| Irani, J | 1 |
| Stopfkuchen-Evans, M | 1 |
| Melnitchouk, N | 1 |
| Hentzen, JEKR | 1 |
| van der Plas, WY | 2 |
| Kuipers, H | 1 |
| Ramcharan, S | 1 |
| Been, LB | 1 |
| Hoogwater, FJH | 1 |
| van Ginkel, RJ | 2 |
| van Dam, GM | 1 |
| Hemmer, PHJ | 3 |
| Kruijff, S | 3 |
| Elekonawo, FMK | 1 |
| van Eden, WJ | 2 |
| Ewalds, RSG | 1 |
| de Jong, LAW | 1 |
| Bremers, AJA | 2 |
| Aalbers, AGJ | 3 |
| Li, XB | 1 |
| Ma, R | 1 |
| Ji, ZH | 2 |
| Lin, YL | 1 |
| Zhang, J | 1 |
| Yang, ZR | 1 |
| Chen, LF | 1 |
| Yan, FC | 1 |
| Blum Murphy, M | 1 |
| Ikoma, N | 1 |
| Estrella, J | 1 |
| Roy-Chowdhuri, S | 1 |
| Das, P | 1 |
| Minsky, BD | 1 |
| Song, S | 1 |
| Ajani, J | 1 |
| Badgwell, B | 1 |
| Archid, R | 1 |
| Zieker, D | 1 |
| Weinreich, FJ | 1 |
| Hönes, F | 1 |
| Königsrainer, A | 1 |
| Quintanilla-Martínez, L | 1 |
| Reymond, MA | 1 |
| Solass, W | 1 |
| Sammartino, P | 2 |
| Ansaloni, L | 1 |
| Asero, S | 1 |
| Baiocchi, G | 1 |
| Bagnoli, P | 1 |
| Cavaliere, D | 1 |
| Framarini, M | 1 |
| Cirocchi, R | 1 |
| Coccolini, F | 1 |
| Decian, F | 1 |
| Delrio, P | 1 |
| Sassaroli, C | 1 |
| De Simone, M | 5 |
| Robella, M | 3 |
| Vaira, M | 4 |
| Di Giorgio, A | 3 |
| Fagotti, A | 1 |
| Lorusso, D | 1 |
| Federici, O | 2 |
| Fiorentini, G | 1 |
| Fambrini, M | 1 |
| Scaringi, S | 2 |
| Garofalo, A | 1 |
| Valle, M | 2 |
| Gelmini, R | 1 |
| Cabry, F | 1 |
| Cautero, N | 1 |
| Sorrentino, L | 1 |
| Graziosi, L | 1 |
| Bartolini, V | 1 |
| Lippolis, PV | 1 |
| Macrì, A | 2 |
| Pasqual, EM | 1 |
| Roviello, F | 2 |
| Marrelli, D | 2 |
| Orsenigo, E | 1 |
| Sommariva, A | 3 |
| Woeste, MR | 1 |
| Philips, P | 1 |
| Egger, ME | 1 |
| Scoggins, CR | 1 |
| McMasters, KM | 1 |
| Martin, RCG | 1 |
| Bakkers, C | 2 |
| van Erning, FN | 1 |
| Rovers, KP | 3 |
| Nienhuijs, SW | 3 |
| Burger, JW | 1 |
| Lemmens, VE | 1 |
| Aalbers, AG | 2 |
| Kok, NF | 1 |
| Boerma, D | 3 |
| Brandt, AR | 1 |
| Hemmer, PH | 1 |
| van Grevenstein, WM | 1 |
| Tuynman, JB | 2 |
| de Hingh, IH | 7 |
| Hulshof, EC | 1 |
| Lurvink, RJ | 2 |
| Caserta, N | 1 |
| van Wezel, T | 1 |
| Böhringer, S | 1 |
| Swen, JJ | 1 |
| Gelderblom, H | 1 |
| Guchelaar, HJ | 1 |
| Deenen, MJ | 1 |
| Zhang, X | 1 |
| Wu, Q | 1 |
| Wei, M | 1 |
| Deng, X | 1 |
| Gu, C | 1 |
| Wang, Z | 1 |
| Soucisse, ML | 1 |
| Lansom, J | 1 |
| Alshahrani, MS | 1 |
| Morris, DL | 13 |
| Carboni, F | 1 |
| Zazza, S | 1 |
| Sperduti, I | 1 |
| Lo Dico, R | 2 |
| Faron, M | 1 |
| Yonemura, Y | 14 |
| Pocard, M | 4 |
| Liberale, G | 1 |
| Kartheuser, A | 2 |
| Sugarbaker, P | 1 |
| Ceelen, W | 3 |
| Quenet, F | 3 |
| Sideris, L | 4 |
| Goere, D | 6 |
| Limbert, M | 1 |
| Nagourney, RA | 1 |
| Evans, S | 1 |
| Tran, PH | 1 |
| Nagourney, AJ | 1 |
| Shariff, US | 1 |
| Chandrakumaran, K | 7 |
| Dayal, S | 3 |
| Mohamed, F | 13 |
| Cecil, TD | 4 |
| Moran, BJ | 5 |
| Arjona-Sanchez, A | 2 |
| Passot, G | 8 |
| Salti, G | 3 |
| Esquivel, J | 6 |
| Piso, P | 7 |
| Nedelcut, DS | 1 |
| Turaga, K | 2 |
| Selvasekar, CR | 1 |
| Rodriguez-Ortiz, L | 1 |
| Sanchez-Hidalgo, JM | 1 |
| Casado-Adam, A | 2 |
| Rufian-Peña, S | 2 |
| Briceño, J | 1 |
| García-Olmo, D | 1 |
| Villarejo Campos, P | 1 |
| Barambio, J | 1 |
| Gomez-Heras, SG | 1 |
| Vega-Clemente, L | 1 |
| Olmedillas-Lopez, S | 1 |
| Guadalajara, H | 1 |
| Garcia-Arranz, M | 1 |
| Barrak, D | 1 |
| Desale, S | 1 |
| Yoon, JJ | 1 |
| Dugan, MM | 1 |
| Kodavanti, PP | 1 |
| Sampah, ME | 1 |
| Loaec, C | 1 |
| Guérin-Charbonnel, C | 1 |
| Vignaud, T | 1 |
| Paineau, J | 1 |
| Thibaudeau, E | 1 |
| Dumont, F | 2 |
| Benzaquen, E | 1 |
| Wang, Y | 1 |
| Wiseman, S | 1 |
| Rosenfeld, V | 1 |
| Dubé, P | 2 |
| Pelletier, JS | 1 |
| Vanounou, T | 1 |
| Zhang, C | 1 |
| Plambeck, BD | 1 |
| Craig, ME | 1 |
| Tu, A | 1 |
| Mikus, RJ | 1 |
| Shostrom, V | 1 |
| McDermott, SP | 1 |
| Igbinigie, I | 1 |
| Brown, K | 1 |
| Cushman-Vokoun, A | 1 |
| Foster, JM | 1 |
| Taibi, A | 1 |
| Perrin, ML | 1 |
| Albouys, J | 1 |
| Jacques, J | 1 |
| Yardin, C | 1 |
| Durand-Fontanier, S | 1 |
| Bardet, SM | 1 |
| Zahid, A | 1 |
| Clarke, L | 1 |
| Carr, N | 1 |
| Tzivanakis, A | 1 |
| Cecil, T | 3 |
| Rotolo, S | 1 |
| Santullo, F | 1 |
| Attalla El Halabieh, M | 1 |
| Lodoli, C | 1 |
| Abatini, C | 1 |
| Pacelli, F | 1 |
| Prabhu, A | 1 |
| Brandl, A | 1 |
| Wakama, S | 1 |
| Sako, S | 1 |
| Ishibashi, H | 2 |
| Mizumoto, A | 2 |
| Takao, N | 1 |
| Ichinose, M | 2 |
| Motoi, S | 1 |
| Liu, Y | 3 |
| Velez-Mejia, C | 1 |
| Sittig, M | 3 |
| Spiliotis, J | 3 |
| Burger, JWA | 1 |
| Creemers, GM | 1 |
| Thijs, AMJ | 1 |
| Brandt-Kerkhof, ARM | 1 |
| Madsen, EVE | 1 |
| van Meerten, E | 1 |
| Kusters, M | 1 |
| Versteeg, KS | 1 |
| Buffart, TE | 1 |
| Wiezer, MJ | 3 |
| Los, M | 1 |
| Verheul, HMW | 1 |
| de Groot, DJA | 1 |
| Witkamp, AJ | 4 |
| Koopman, M | 1 |
| Nederend, J | 1 |
| Lahaye, MJ | 1 |
| Kranenburg, O | 2 |
| Fijneman, RJA | 1 |
| van 't Erve, I | 1 |
| Snaebjornsson, P | 1 |
| Dijkgraaf, MGW | 1 |
| Punt, CJA | 1 |
| van de Vlasakker, VCJ | 1 |
| Cashin, PH | 1 |
| González-Moreno, S | 4 |
| Lehmann, K | 1 |
| Quadros, CA | 1 |
| Rau, B | 3 |
| Teo, MCC | 2 |
| Verwaal, VJ | 6 |
| Wu, V | 1 |
| Shen, J | 1 |
| Chung, SY | 1 |
| Saif, MW | 1 |
| Gajardo, JA | 1 |
| Matute, J | 1 |
| Charles, R | 1 |
| Devaud, N | 1 |
| Hoefler, S | 1 |
| Schmied, S | 1 |
| Rigo-Righi, D | 1 |
| Butte, JM | 1 |
| Ashraf-Kashani, N | 1 |
| Bell, J | 1 |
| Eng, OS | 1 |
| Dumitra, S | 1 |
| O'Leary, M | 1 |
| Wakabayashi, M | 1 |
| Dellinger, TH | 1 |
| Han, ES | 1 |
| Benjamin Paz, I | 1 |
| Singh, G | 1 |
| Lee, B | 1 |
| Lange, KN | 1 |
| McKay, D | 1 |
| Gentry, BG | 1 |
| Franko, J | 1 |
| Feferman, Y | 1 |
| Bhagwandin, S | 2 |
| Kim, J | 1 |
| Aycart, SN | 2 |
| Feingold, D | 1 |
| Labow, DM | 3 |
| Sarpel, U | 3 |
| Morales-Soriano, R | 1 |
| Esteve-Pérez, N | 1 |
| Segura-Sampedro, JJ | 1 |
| Cascales-Campos, P | 1 |
| Barrios, P | 1 |
| Woensdregt, K | 1 |
| Huitema, ADR | 1 |
| Boot, H | 4 |
| Kozman, MA | 1 |
| Fisher, OM | 1 |
| Rebolledo, BJ | 1 |
| Parikh, R | 1 |
| Valle, SJ | 1 |
| Arrowaili, A | 1 |
| Alzahrani, N | 1 |
| Liauw, W | 5 |
| Malgras, B | 1 |
| Gayat, E | 1 |
| Aoun, O | 1 |
| Eveno, C | 3 |
| Pautrat, K | 1 |
| Marchal, F | 1 |
| Sgarbura, O | 1 |
| Ferron, G | 2 |
| Andre, T | 1 |
| Rana, AKS | 1 |
| Agarwal, N | 1 |
| Dutta, S | 1 |
| Dokania, MK | 1 |
| Goyal, H | 1 |
| Thorgersen, EB | 1 |
| Melum, E | 1 |
| Folseraas, T | 1 |
| Line, PD | 1 |
| Mahmoud, AM | 2 |
| Ismail, YM | 1 |
| Hussien, A | 1 |
| Debaky, Y | 1 |
| Ahmed, IS | 1 |
| Mikhael, HSW | 1 |
| Moneer, M | 1 |
| García, KM | 1 |
| Flores, KM | 1 |
| Ruiz, A | 1 |
| González, FL | 1 |
| Rodríguez, ÁM | 1 |
| Sipok, A | 1 |
| Pham, T | 1 |
| Craig Lynch, A | 1 |
| Tie, J | 1 |
| Frøysnes, IS | 2 |
| Andersson, Y | 2 |
| Davidson, B | 1 |
| Øien, JT | 1 |
| Julsrud, L | 1 |
| Fodstad, Ø | 2 |
| Schubert, J | 1 |
| Khosrawipour, V | 1 |
| Chaudhry, H | 1 |
| Arafkas, M | 1 |
| Knoefel, WT | 1 |
| Pigazzi, A | 1 |
| Khosrawipour, T | 1 |
| Ubink, I | 1 |
| Bolhaqueiro, ACF | 1 |
| Elias, SG | 1 |
| Raats, DAE | 1 |
| Constantinides, A | 1 |
| Peters, NA | 1 |
| Wassenaar, ECE | 1 |
| Laclé, MM | 1 |
| Kops, GJPL | 1 |
| Borel Rinkes, IHM | 1 |
| Shannon, NB | 1 |
| Tan, JW | 1 |
| Tan, HL | 1 |
| Wang, W | 3 |
| Chen, Y | 1 |
| Lim, HJ | 1 |
| Tan, QX | 1 |
| Hendrikson, J | 1 |
| Ng, WH | 1 |
| Loo, LY | 1 |
| Skanthakumar, T | 1 |
| Wasudevan, SD | 1 |
| Kon, OL | 1 |
| Lim, TKH | 1 |
| Tan, GHC | 1 |
| Chia, CS | 2 |
| Soo, KC | 2 |
| Ong, CJ | 1 |
| Turner, KM | 1 |
| Hanna, NN | 1 |
| Zhu, Y | 1 |
| Jain, A | 1 |
| Kesmodel, SB | 1 |
| Switzer, RA | 1 |
| Taylor, LM | 1 |
| Richard Alexander, H | 1 |
| Iversen, LH | 2 |
| Rasmussen, PC | 2 |
| Hagemann-Madsen, R | 1 |
| Laurberg, S | 2 |
| Guldvik, IJ | 1 |
| Svensson, H | 1 |
| Fleten, KG | 1 |
| Flørenes, VA | 1 |
| Reed, W | 1 |
| Kepenekian, V | 2 |
| Aloy, MT | 1 |
| Magné, N | 1 |
| Armandy, E | 1 |
| Decullier, E | 1 |
| Sayag-Beaujard, A | 2 |
| Gilly, FN | 16 |
| Rodriguez-Lafrasse, C | 1 |
| Hutanu, I | 2 |
| Chua, TC | 5 |
| Quinn, LE | 1 |
| Zhao, J | 2 |
| Swords, DS | 1 |
| Swett, KR | 1 |
| Randle, RW | 1 |
| Cabras, AD | 2 |
| Bertulli, R | 2 |
| Faris, JE | 1 |
| Ryan, DP | 1 |
| Järvinen, P | 1 |
| Ristimäki, A | 1 |
| Kantonen, J | 1 |
| Lepistö, A | 1 |
| Jimenez, WA | 1 |
| Macdonald, R | 1 |
| Taflampas, P | 1 |
| Riss, S | 1 |
| Magge, D | 1 |
| Zenati, MS | 1 |
| Austin, F | 2 |
| Mavanur, A | 2 |
| Sathaiah, M | 2 |
| Ramalingam, L | 3 |
| Jones, H | 1 |
| Zureikat, AH | 2 |
| Holtzman, M | 2 |
| Ahrendt, S | 2 |
| Pingpank, J | 2 |
| Zeh, HJ | 3 |
| Choudry, HA | 4 |
| Bakrin, N | 6 |
| Roux, AS | 1 |
| Vaudoyer, D | 3 |
| Cotte, E | 9 |
| Hompes, D | 2 |
| D'Hoore, A | 2 |
| Wolthuis, A | 2 |
| Fieuws, S | 2 |
| Mirck, B | 1 |
| Bruin, S | 1 |
| Verwaal, V | 1 |
| Shimizu, T | 1 |
| Sonoda, H | 1 |
| Murata, S | 1 |
| Takebayashi, K | 1 |
| Ohta, H | 1 |
| Miyake, T | 1 |
| Mekata, E | 1 |
| Shiomi, H | 1 |
| Naka, S | 1 |
| Tani, T | 1 |
| Russell, GB | 10 |
| Loggie, BL | 2 |
| Tabrizian, P | 1 |
| Shrager, B | 1 |
| Jibara, G | 1 |
| Yang, MJ | 1 |
| Romanoff, A | 1 |
| Hiotis, S | 2 |
| Feist, M | 1 |
| Huang, X | 1 |
| Müller, JM | 1 |
| Dubiel, W | 1 |
| Van Nieuwenhove, Y | 1 |
| Putte, DV | 1 |
| Pattyn, P | 1 |
| Shetty, SJ | 1 |
| Bathla, L | 1 |
| Govindarajan, V | 1 |
| Thomas, P | 1 |
| Loggie, BW | 11 |
| Garcia, SS | 1 |
| Hicken, W | 1 |
| Seibel, J | 1 |
| Shekitka, K | 1 |
| Trout, R | 2 |
| Song, X | 1 |
| Dilly, AK | 1 |
| Kim, SY | 1 |
| Lee, YJ | 1 |
| Iusco, D | 1 |
| Bonomi, S | 2 |
| Grassi, A | 2 |
| Virzì, S | 2 |
| Leo, E | 1 |
| Teo, MC | 2 |
| Ching Tan, GH | 1 |
| Lim, C | 1 |
| Tham, CK | 1 |
| Sloothaak, DA | 1 |
| Gardenbroek, TJ | 1 |
| Crezee, J | 1 |
| Bemelman, WA | 1 |
| Punt, CJ | 1 |
| Buskens, CJ | 1 |
| Prada-Villaverde, A | 1 |
| Lowy, AM | 1 |
| Markman, M | 1 |
| Chua, T | 1 |
| Pelz, J | 1 |
| Baumgartner, JM | 2 |
| Berri, R | 1 |
| Bretcha-Boix, P | 1 |
| Flores-Ayala, G | 1 |
| Gomez-Portilla, A | 1 |
| Goodman, M | 1 |
| Halkia, E | 1 |
| Moller, M | 1 |
| Senthil, M | 2 |
| Torres-Melero, J | 1 |
| Berger, Y | 2 |
| Zbar, AP | 1 |
| Lebedyev, A | 1 |
| Levi, Y | 1 |
| Nevler, A | 1 |
| Aderka, D | 1 |
| Golan, T | 1 |
| Purim, O | 1 |
| Brenner, B | 1 |
| Natur, M | 1 |
| Gutman, M | 1 |
| Lord, AC | 1 |
| Shihab, O | 1 |
| Huang, CQ | 2 |
| Yang, XJ | 3 |
| Yu, Y | 1 |
| Wu, HT | 2 |
| Abdul Aziz, NH | 1 |
| Mellano, A | 1 |
| Sottile, A | 1 |
| Naffouje, S | 1 |
| Hirano, M | 1 |
| Takeshita, K | 1 |
| Nishino, E | 1 |
| Kashu, I | 1 |
| Yamamoto, Y | 1 |
| Sparks, DS | 1 |
| Morris, B | 1 |
| Xu, W | 1 |
| Fulton, J | 1 |
| Atkinson, V | 1 |
| Meade, B | 1 |
| Lutton, N | 1 |
| Triki, E | 1 |
| Meyer, N | 2 |
| Kwakman, R | 1 |
| de Cuba, EM | 1 |
| de Winter, JP | 1 |
| Delis-van Diemen, PM | 1 |
| Tijssen, M | 1 |
| Rooimans, MA | 1 |
| Krijgsman, O | 1 |
| Carvalho, B | 1 |
| Peters, GJ | 1 |
| Bonjer, HJ | 1 |
| Meijer, GA | 1 |
| Te Velde, EA | 1 |
| van Vugt, JL | 1 |
| Braam, HJ | 1 |
| van Oudheusden, TR | 1 |
| Vestering, A | 1 |
| Bollen, TL | 1 |
| van Ramshorst, B | 2 |
| Arnold, S | 1 |
| Venkatasubramaniam, A | 1 |
| Roberts, DL | 1 |
| Stern, PL | 1 |
| Renehan, AG | 2 |
| Kemmel, V | 1 |
| Mercoli, HA | 1 |
| Brumaru, D | 1 |
| Lessinger, JM | 1 |
| Sabourin, JC | 1 |
| Bjersand, K | 1 |
| Mahteme, H | 4 |
| Sundström Poromaa, I | 1 |
| Andréasson, H | 1 |
| Graf, W | 3 |
| Larsson, R | 2 |
| Nygren, P | 2 |
| Huang, Y | 2 |
| Alzahrani, NA | 1 |
| Bouhadjari, N | 1 |
| Gabato, W | 1 |
| Calabrese, D | 1 |
| Msika, S | 2 |
| Keita, H | 1 |
| Dineen, SP | 1 |
| Robinson, KA | 1 |
| Roland, CL | 1 |
| Beaty, KA | 1 |
| Rafeeq, S | 1 |
| Mansfield, PF | 2 |
| Royal, RE | 1 |
| Fournier, KF | 1 |
| Kuijpers, AM | 1 |
| Hauptmann, M | 1 |
| Havenga, K | 1 |
| Korakianitis, O | 1 |
| Daskalou, T | 1 |
| Alevizos, L | 1 |
| Stamou, K | 1 |
| Mavroudis, C | 1 |
| Iatrou, C | 1 |
| Vogiatzaki, T | 1 |
| Eleftheriadis, S | 1 |
| Tentes, AA | 1 |
| Bespalov, VG | 1 |
| Vyshinskaya, EA | 1 |
| Vasilieva, IN | 1 |
| Maidin, MA | 1 |
| Semenov, AL | 1 |
| Stukov, AN | 1 |
| Kireeva, GS | 1 |
| Belyaeva, OA | 1 |
| Kopteva, OS | 1 |
| Krasilnikova, LA | 1 |
| Alexandrov, VA | 1 |
| Belyaev, AM | 1 |
| Charrier, T | 1 |
| Peron, J | 1 |
| Maurice, C | 1 |
| Gocevska, S | 1 |
| Elias, D | 6 |
| Ortega-Deballon, P | 2 |
| Sun, JH | 1 |
| Peng, KW | 1 |
| Zhang, Q | 1 |
| Koyama, M | 1 |
| Yano, T | 1 |
| Kikuchi, K | 1 |
| Mizuno, M | 1 |
| Nagano, N | 1 |
| Hashimoto, A | 1 |
| Miura, T | 1 |
| Tuvin, D | 1 |
| Shtilbans, T | 1 |
| Spasojevic, M | 1 |
| Kim, BJ | 1 |
| Bonnefoy, I | 1 |
| Di Fabio, F | 1 |
| Mehta, A | 1 |
| Navez, J | 1 |
| Remue, C | 1 |
| Leonard, D | 1 |
| Bachmann, R | 1 |
| Hubert, C | 1 |
| Coubeau, L | 1 |
| Komuta, M | 1 |
| Van den Eynde, M | 1 |
| Zech, F | 1 |
| Jabbour, N | 1 |
| Hussein, MM | 1 |
| Moneer, MM | 1 |
| Leung, V | 1 |
| Huo, YR | 1 |
| Massalou, D | 1 |
| Benizri, E | 2 |
| Chevallier, A | 1 |
| Duranton-Tanneur, V | 1 |
| Pedeutour, F | 1 |
| Benchimol, D | 2 |
| Béréder, JM | 3 |
| Ihemelandu, C | 2 |
| Lin, EK | 1 |
| Hsieh, MC | 1 |
| Chen, CH | 1 |
| Lu, YJ | 1 |
| Wu, SY | 1 |
| Abel, ML | 1 |
| Kokosis, G | 1 |
| Blazer, DG | 1 |
| Aghayeva, A | 1 |
| Benlice, C | 1 |
| Bilgin, IA | 1 |
| Atukeren, P | 1 |
| Dogusoy, G | 1 |
| Demir, F | 1 |
| Atasoy, D | 1 |
| Baca, B | 1 |
| Farquharson, AL | 1 |
| Pranesh, N | 1 |
| Witham, G | 1 |
| Swindell, R | 1 |
| Taylor, MB | 1 |
| Rout, S | 1 |
| Wilson, MS | 1 |
| Saunders, MP | 1 |
| Aarts, F | 2 |
| Bleichrodt, RP | 4 |
| de Man, B | 1 |
| Lomme, R | 1 |
| Boerman, OC | 2 |
| Hendriks, T | 4 |
| al-shammaa Hassan, AH | 1 |
| Yang, GL | 2 |
| Liu, SY | 1 |
| Lu, YL | 1 |
| Zhang, JW | 1 |
| Dileo, P | 1 |
| Laterza, B | 5 |
| Lanuke, K | 1 |
| Mack, LA | 2 |
| Temple, WJ | 2 |
| Mitchell, A | 1 |
| Drolet, P | 1 |
| Leblanc, G | 1 |
| Leclerc, YE | 1 |
| Varban, O | 1 |
| McCoy, TP | 1 |
| Gammon, DC | 1 |
| Dutton, T | 1 |
| Piperdi, B | 1 |
| Zybert, J | 1 |
| Wolfe, SH | 1 |
| Nguyen, E | 1 |
| Sbat, D | 1 |
| Pillarisetty, VG | 1 |
| Sullivan, M | 1 |
| Whalen, GF | 1 |
| Mirnezami, AH | 1 |
| Simon, L | 1 |
| Halilou, MC | 1 |
| Gladieff, L | 1 |
| Gadiou, M | 1 |
| Herin, F | 1 |
| Hennebelle, I | 1 |
| Chatelut, E | 1 |
| Harrison, LE | 2 |
| Raue, W | 1 |
| Kilian, M | 1 |
| Atanassow, V | 1 |
| Makareinis, A | 1 |
| Caldenas, S | 1 |
| Schwenk, W | 1 |
| Hartmann, J | 1 |
| Kanagavel, D | 1 |
| Pokataev, IA | 1 |
| Fedyanin, MY | 1 |
| Tryakin, AA | 1 |
| Bazin, IS | 1 |
| Narimanov, MN | 1 |
| Yakovleva, ES | 1 |
| Garin, AM | 1 |
| Tjulandin, SA | 1 |
| Colomban, O | 1 |
| Guitton, J | 1 |
| Tranchand, B | 1 |
| Tod, M | 2 |
| Gilly, F | 2 |
| Mansvelt, B | 2 |
| Lorimier, G | 1 |
| Blackham, AU | 1 |
| Pennacchioli, E | 2 |
| Fiore, M | 1 |
| Balestra, MR | 1 |
| Colombo, C | 1 |
| Mingrone, E | 1 |
| Gronchi, A | 1 |
| Alessanrdro, G | 1 |
| Rueth, NM | 1 |
| Murray, SE | 1 |
| Huddleston, SJ | 1 |
| Abbott, AM | 1 |
| Greeno, EW | 1 |
| Kirstein, MN | 1 |
| Tuttle, TM | 2 |
| Al-Zahrani, A | 1 |
| Saxena, A | 1 |
| Klaver, YL | 3 |
| Lomme, RM | 2 |
| Rutten, HJ | 2 |
| Noura, S | 1 |
| Ohue, M | 1 |
| Shingai, T | 1 |
| Kano, S | 1 |
| Ohigashi, H | 2 |
| Yano, M | 3 |
| Ishikawa, O | 2 |
| Takenaka, A | 2 |
| Murata, K | 1 |
| Kameyama, M | 3 |
| Stuart, OA | 6 |
| Chang, D | 4 |
| Raudrant, D | 1 |
| Isaac, S | 3 |
| Glockzin, G | 2 |
| Renner, P | 1 |
| Popp, FC | 1 |
| Dahlke, MH | 3 |
| von Breitenbuch, P | 2 |
| Schlitt, HJ | 4 |
| Sakamoto, H | 1 |
| Amikura, K | 1 |
| Tanaka, Y | 1 |
| Nishimura, Y | 1 |
| Kawashima, Y | 1 |
| Yatsuoka, T | 1 |
| Yamagata, Y | 1 |
| Yamaura, T | 1 |
| Yokoyama, Y | 1 |
| Akiyama, H | 2 |
| Nakajima, T | 1 |
| Levine, E | 1 |
| Hayes-Jordan, A | 1 |
| Facy, A | 1 |
| Rat, P | 1 |
| Steghens, A | 1 |
| Suo, T | 1 |
| Mei, LJ | 1 |
| Cheng, FL | 1 |
| Zhou, YF | 1 |
| Xiong, B | 1 |
| Parson, EN | 1 |
| Lentz, S | 1 |
| Muñoz-Casares, FC | 1 |
| Díaz-Nieto, R | 1 |
| Rubio-Pérez, MJ | 1 |
| Ortega-Salas, R | 1 |
| Mohr, Z | 1 |
| Hirche, C | 1 |
| Liebeskind, U | 1 |
| Hünerbein, M | 1 |
| Kitai, T | 1 |
| Kawashima, M | 1 |
| Yamanaka, K | 1 |
| Ichijima, K | 1 |
| Fujii, H | 1 |
| Mashima, S | 1 |
| Shimahara, Y | 1 |
| Krane, LS | 1 |
| Kader, AK | 1 |
| Steel, J | 1 |
| Lenzner, D | 1 |
| Weber, T | 1 |
| Roitman, M | 1 |
| Link, KH | 1 |
| Votanopoulos, K | 1 |
| Stewart, J | 1 |
| Iusco, DR | 1 |
| Puccio, F | 1 |
| Famulari, C | 1 |
| Solazzo, M | 1 |
| Tiek, J | 1 |
| Penninckx, F | 1 |
| Van Cutsem, E | 1 |
| Dartigues, P | 1 |
| Honoré, C | 2 |
| Tzanis, D | 1 |
| Benhaim, L | 1 |
| Malka, D | 2 |
| McConnell, YJ | 1 |
| Francis, WP | 1 |
| Ho, T | 1 |
| Tiesi, G | 1 |
| Razavi, R | 1 |
| Wang, CC | 1 |
| Benizri, EI | 1 |
| Rahili, A | 1 |
| Bernard, JL | 1 |
| Ahrendt, SA | 1 |
| Pingpank, JF | 1 |
| Holtzman, MP | 1 |
| Jones, HL | 1 |
| Fushida, S | 5 |
| Nao, F | 1 |
| Kinami, S | 3 |
| Ninomiya, I | 2 |
| Fujimura, T | 6 |
| Nishimura, G | 2 |
| Ohta, T | 2 |
| Yokogawa, K | 1 |
| Miyamoto, K | 1 |
| Miwa, K | 3 |
| Fu, QG | 1 |
| Meng, FD | 1 |
| Shen, XD | 1 |
| Guo, RX | 1 |
| Sutton, SW | 1 |
| Yancey, LW | 1 |
| Chase, VA | 1 |
| Hunley, EK | 1 |
| McCarty, TM | 1 |
| Kuhn, JA | 1 |
| Kunisaki, C | 1 |
| Nomura, M | 1 |
| Matsuda, G | 1 |
| Otsuka, Y | 1 |
| Ono, H | 1 |
| Shimada, H | 1 |
| Hall, J | 1 |
| Case, D | 1 |
| Fleming, R | 1 |
| Geisinger, KR | 5 |
| Mithieux, F | 1 |
| Osinsky, D | 3 |
| Beaujard, AC | 2 |
| Freyer, G | 3 |
| Guertsch, P | 1 |
| Francois, Y | 6 |
| Peyrat, P | 1 |
| Panteix, G | 4 |
| Vignal, J | 7 |
| McQuellon, RP | 6 |
| Lehman, AB | 2 |
| Fleming, RA | 8 |
| de Lima Vazquez, V | 1 |
| Pilati, P | 1 |
| Mocellin, S | 1 |
| Rossi, CR | 4 |
| Foletto, M | 1 |
| Campana, L | 1 |
| Nitti, D | 1 |
| Lise, M | 1 |
| Casali, P | 2 |
| Inglese, MG | 1 |
| Stamou, KM | 1 |
| Karakozis, S | 1 |
| Kwiatkowski, F | 1 |
| Trillet-Lenoir, V | 1 |
| Sayag-Beaujard, AC | 7 |
| van Ruth, S | 2 |
| Zoetmulder, FA | 7 |
| Douglass, HO | 1 |
| Mori, T | 1 |
| Fujiwara, Y | 1 |
| Sugita, Y | 1 |
| Azama, T | 1 |
| Ishii, T | 1 |
| Taniguchi, K | 1 |
| Yamazaki, K | 1 |
| Takiguchi, S | 1 |
| Yasuda, T | 2 |
| Monden, M | 2 |
| Schreiber, V | 2 |
| Hawksworth, J | 1 |
| Lovato, J | 1 |
| Chung, NC | 1 |
| Liu, YC | 1 |
| Ye, XD | 1 |
| Wang, YM | 1 |
| Kuo, MC | 1 |
| Liu, K | 1 |
| Gething, S | 1 |
| Haiba, M | 1 |
| Brun, EA | 1 |
| Antos, F | 1 |
| Serclova, Z | 1 |
| Gilbert, Z | 1 |
| Skala, M | 1 |
| Vitek, P | 1 |
| Müller, H | 1 |
| Nakchbandi, V | 1 |
| Hribaschek, A | 2 |
| Pross, M | 2 |
| Ridwelski, K | 3 |
| Meyer, F | 2 |
| Fenske, A | 1 |
| Krüger, S | 1 |
| Lippert, H | 3 |
| Nakamura, T | 1 |
| Shimada, K | 1 |
| Okubo, Y | 1 |
| Tanaka, S | 1 |
| Tanabe, S | 1 |
| Yoshida, M | 1 |
| Doi, K | 1 |
| Uchinami, M | 1 |
| Horiuchi, T | 1 |
| Tanaka, K | 2 |
| Güner, Z | 1 |
| Schmidt, U | 2 |
| Klempnauer, J | 2 |
| Ohgaki, M | 2 |
| Shiomi, A | 1 |
| Chou, H | 1 |
| Takashina, K | 1 |
| Kawakami, S | 1 |
| Fujita, Y | 1 |
| Hagiwara, A | 10 |
| Yamagishi, H | 1 |
| Sadeghi-Looyeh, B | 2 |
| Bienvenu, J | 4 |
| Garbit, F | 3 |
| Grandclément, E | 3 |
| Banssillon, V | 2 |
| de Bree, E | 3 |
| Romanos, J | 1 |
| Relakis, K | 1 |
| Tsiftsis, DD | 1 |
| Kecmanovic, DM | 1 |
| Pavlov, MJ | 1 |
| Ceranic, MS | 1 |
| Sepetkovski, AV | 1 |
| Kovacevic, PA | 1 |
| Stamenkovic, AB | 1 |
| Gebauer, T | 1 |
| Grote, R | 1 |
| Martens-Lobenhoffer, J | 1 |
| Izzo, L | 1 |
| Pierannunzi, F | 1 |
| Vari, A | 1 |
| Riccardi, S | 1 |
| Tarquini, S | 1 |
| Fermariello, A | 1 |
| Casullo, A | 1 |
| Caputo, M | 1 |
| Costi, U | 1 |
| Al Radhi, H | 1 |
| Kharrub, Z | 1 |
| Gazzanelli, S | 1 |
| Brun, E | 1 |
| Witkamp, A | 1 |
| van Slooten, G | 1 |
| Loungnarath, R | 1 |
| Causeret, S | 1 |
| Bossard, N | 1 |
| Faheez, M | 1 |
| Pelz, JO | 4 |
| Doerfer, J | 2 |
| Hohenberger, W | 3 |
| Meyer, T | 3 |
| Alexander-Sefre, F | 1 |
| Banerjee, S | 1 |
| Sexton, R | 1 |
| Thomas, JM | 1 |
| Mizuta, Y | 1 |
| Akazawa, Y | 1 |
| Shiozawa, K | 1 |
| Ohara, H | 1 |
| Ohba, K | 1 |
| Ohnita, K | 1 |
| Isomoto, H | 1 |
| Takeshima, F | 1 |
| Omagari, K | 1 |
| Yasutake, T | 1 |
| Nakagoe, T | 1 |
| Shirono, K | 1 |
| Kohno, S | 1 |
| Sawada, T | 1 |
| Nishimura, M | 1 |
| Hirose, K | 2 |
| Carmignani, CP | 1 |
| Smeenk, RM | 1 |
| Fujita, H | 2 |
| Giuliani, F | 1 |
| Molica, S | 1 |
| Maiello, E | 1 |
| Battaglia, C | 1 |
| Gebbia, V | 1 |
| Di Bisceglie, M | 1 |
| Vinciarelli, G | 1 |
| Gebbia, N | 1 |
| Colucci, G | 1 |
| Yoo, D | 2 |
| Cerretani, D | 1 |
| Nencini, C | 1 |
| Urso, R | 1 |
| Giorgi, G | 1 |
| De Stefano, A | 1 |
| Pinto, E | 1 |
| Cioppa, T | 1 |
| Nastri, G | 1 |
| Nonaka, D | 2 |
| Rosai, J | 1 |
| Younan, R | 4 |
| Salvatore, A | 1 |
| Cabras Ad, AD | 1 |
| Costanzo, P | 2 |
| Favaro, M | 3 |
| Gavazzi, C | 4 |
| Aiko, S | 1 |
| Yoshizumi, Y | 1 |
| Sugiura, Y | 1 |
| Ishizuka, T | 1 |
| Sakano, T | 1 |
| Kumano, I | 1 |
| Maehara, T | 1 |
| Monneuse, O | 1 |
| Alderman, R | 1 |
| Edwards, G | 1 |
| Marquardt, CE | 1 |
| Yu, W | 1 |
| Yan, TD | 5 |
| Cavaliere, F | 5 |
| Di Filippo, F | 4 |
| Piatti, P | 1 |
| Difilippo, F | 1 |
| Scuderi, S | 1 |
| Pilatti, P | 1 |
| Perri, P | 2 |
| Pilati, PL | 1 |
| Aloe, S | 1 |
| Di Filippo, S | 1 |
| Schmid, K | 1 |
| Boettcher, MI | 2 |
| Korinth, G | 1 |
| Angerer, J | 1 |
| Drexler, H | 1 |
| Dimmler, A | 1 |
| Links, M | 2 |
| Xu, ZY | 1 |
| Kam, PC | 2 |
| Glenn, D | 2 |
| Chu, F | 1 |
| Zhang, Y | 1 |
| Greeno, E | 1 |
| Knutsen, A | 1 |
| Qu, ZB | 1 |
| Liu, LX | 1 |
| Di Pietrantonio, D | 2 |
| Menegon, P | 1 |
| Raynard, B | 2 |
| da Silva, RG | 1 |
| Danhauer, SC | 1 |
| Fenstermaker, J | 1 |
| Pérez, J | 1 |
| Rodríguez, MJ | 1 |
| Campaña, O | 1 |
| Veiras, S | 1 |
| Lorenzo, D | 1 |
| Lamas, M | 1 |
| Alvarez, J | 1 |
| Dang, A | 1 |
| Ilsin, B | 1 |
| Hightower, C | 1 |
| Aravindan, N | 1 |
| Rice, D | 1 |
| Riedel, B | 1 |
| Lambert, LA | 1 |
| Bijelic, L | 2 |
| Martinetti, A | 1 |
| Seregni, E | 1 |
| Oliva, DG | 1 |
| Oliva, GD | 2 |
| Grosso, F | 1 |
| von Heideman, A | 1 |
| Grundmark, B | 1 |
| Tholander, B | 1 |
| Påhlman, L | 2 |
| Glimelius, B | 1 |
| Koppe, MJ | 1 |
| Oyen, WJ | 1 |
| Reingruber, B | 1 |
| Klein, P | 1 |
| Antonucci, A | 1 |
| Saunders, W | 1 |
| Langer, M | 1 |
| Andreola, S | 1 |
| van Leeuwen, BL | 1 |
| Kianmanesh, R | 1 |
| Sabate, JM | 1 |
| Facchiano, E | 1 |
| Jouet, P | 1 |
| Coffin, B | 1 |
| Parmentier, G | 1 |
| Hay, JM | 1 |
| Flamant, Y | 1 |
| Wagner, OJ | 1 |
| Inglin, RA | 1 |
| Bisch-Knaden, S | 1 |
| Mettler, D | 1 |
| Borner, M | 1 |
| Candinas, D | 1 |
| Egger, B | 1 |
| Boulet, T | 1 |
| Bonnet, S | 1 |
| Kohneh-Shahri, N | 1 |
| Hesdorffer, ME | 1 |
| Chabot, JA | 1 |
| Keohan, ML | 1 |
| Fountain, K | 1 |
| Talbot, S | 1 |
| Gabay, M | 1 |
| Valentin, C | 1 |
| Lee, SM | 1 |
| Taub, RN | 1 |
| Lim, ST | 1 |
| Jeong, HJ | 1 |
| Kim, DW | 1 |
| Yim, CY | 1 |
| Sohn, MH | 1 |
| Hamazoe, R | 5 |
| Koga, S | 4 |
| Maeta, M | 4 |
| Shimizu, N | 2 |
| Sumi, K | 1 |
| Oda, M | 1 |
| Karino, T | 1 |
| Yamane, T | 1 |
| Kanayama, H | 1 |
| Osaki, Y | 1 |
| Sato, M | 1 |
| Ishidoya, T | 1 |
| Joko, Y | 1 |
| Kiyasu, Y | 1 |
| Sakai, K | 1 |
| Kimura, S | 1 |
| Van Weelde, BJ | 1 |
| Pauwels, EK | 1 |
| Jones, B | 1 |
| Van Oosterom, AT | 1 |
| Fornasiero, A | 1 |
| Cartei, G | 1 |
| Daniele, O | 1 |
| Fosser, V | 1 |
| Fiorentino, MV | 1 |
| Takahashi, T | 12 |
| Kitamura, M | 6 |
| Arai, K | 8 |
| Iwasaki, Y | 5 |
| Nakagawara, H | 1 |
| Itoh, H | 1 |
| Hirono, Y | 1 |
| Kaji, M | 1 |
| Nakai, M | 1 |
| Adachi, W | 1 |
| Koike, S | 2 |
| Rafique, M | 1 |
| Kajikawa, S | 1 |
| Kaneko, G | 1 |
| Kuroda, T | 1 |
| Iida, F | 1 |
| Ishii, K | 1 |
| Kuzuya, T | 2 |
| Yamauchi, M | 2 |
| Ito, A | 2 |
| Hasegawa, M | 2 |
| Hasegawa, T | 1 |
| Nabeshima, T | 1 |
| Jablonski, KA | 1 |
| Imanishi, T | 1 |
| Ohyama, T | 1 |
| Tsujimoto, H | 2 |
| Ozaki, K | 3 |
| Chohei, S | 1 |
| Shimotsuma, M | 4 |
| Maehara, Y | 1 |
| Okuyama, T | 1 |
| Kakeji, Y | 1 |
| Baba, H | 1 |
| Furusawa, M | 1 |
| Sugimachi, K | 1 |
| Carry, PY | 2 |
| Sayag, AC | 1 |
| Brachet, A | 2 |
| Salle, B | 2 |
| Burgard, G | 1 |
| Guibert, B | 1 |
| Kaibara, N | 4 |
| Sayag, A | 1 |
| Braillon, G | 1 |
| Miyashita, K | 3 |
| Sakakibara, T | 1 |
| Oyama, T | 1 |
| Sasaki, S | 1 |
| Sakakura, C | 1 |
| Schneebaum, S | 2 |
| Arnold, MW | 2 |
| Staubus, A | 1 |
| Young, DC | 1 |
| Dumond, D | 1 |
| Martin, EW | 2 |
| Fernández-Trigo, V | 1 |
| Stephens, AD | 1 |
| Hoover, LD | 1 |
| Koslowe, P | 1 |
| Yamaguchi, T | 3 |
| Fujimoto, S | 12 |
| Takahashi, M | 10 |
| Kobayashi, K | 12 |
| Kasanuki, J | 1 |
| Ohkubo, H | 3 |
| Staubus, AE | 1 |
| Nonaka, M | 1 |
| Oosawa, J | 1 |
| Nakanishi, M | 1 |
| Kamiyama, J | 1 |
| Idoguchi, K | 1 |
| Tabata, T | 1 |
| Okuno, T | 1 |
| Itoshima, T | 1 |
| Sasaki, A | 2 |
| Terashima, M | 2 |
| Okamoto, K | 2 |
| Ikeda, K | 2 |
| Takagane, A | 2 |
| Takiyama, I | 2 |
| Kuboi, M | 1 |
| Sasaki, N | 2 |
| Saito, K | 2 |
| Perini, M | 1 |
| Geisinger, K | 1 |
| Mutou, T | 1 |
| Toyosawa, T | 2 |
| Isawa, E | 1 |
| Sumida, M | 1 |
| Chung, YC | 1 |
| Huang, MT | 1 |
| Chang, CN | 1 |
| Huang, TW | 1 |
| Chen, MY | 1 |
| Chiles, C | 1 |
| Choplin, RH | 1 |
| Perini, MA | 1 |
| Bertrand, C | 1 |
| Nockerman, P | 1 |
| Arnould, P | 1 |
| Delvaux, P | 1 |
| Lechien, X | 1 |
| de Neve de Roden, A | 1 |
| Tsujinaka, T | 1 |
| Shiozaki, H | 1 |
| Inoue, M | 1 |
| Doki, Y | 1 |
| Taniguchi, M | 1 |
| Murata, A | 1 |
| Tsushima, K | 1 |
| Sakata, Y | 1 |
| Kan, K | 1 |
| Naitoh, K | 1 |
| Tsuruta, A | 1 |
| Mizuta, N | 1 |
| Ohmori, K | 1 |
| Kawachi, H | 1 |
| Amaike, H | 1 |
| Yanada, M | 1 |
| Ohmori, Y | 1 |
| Muto, T | 1 |
| Rosen, HR | 1 |
| Jatzko, G | 1 |
| Repse, S | 1 |
| Potrc, S | 1 |
| Neudorfer, H | 1 |
| Sandbichler, P | 1 |
| Zacherl, J | 1 |
| Rabl, H | 1 |
| Holzberger, P | 1 |
| Lisborg, P | 1 |
| Czeijka, M | 1 |
| Arnaud, JP | 1 |
| Peyrat, PP | 1 |
| Fass, J | 1 |
| Jansen, M | 1 |
| Zengel, K | 1 |
| Reinecke, T | 1 |
| Asshoff, G | 1 |
| Schumpelick, V | 1 |
| Igarashi, N | 1 |
| Kubota, T | 1 |
| Otani, Y | 1 |
| Matsuzaki, SW | 1 |
| Watanabe, M | 1 |
| Teramoto, T | 1 |
| Kumai, K | 1 |
| Tamaki, K | 1 |
| Tanzawa, K | 1 |
| Kobayashi, T | 1 |
| Kitajima, M | 1 |
| Hosch, WP | 1 |
| Rudi, J | 1 |
| Stremmel, W | 1 |
| Katayama, K | 4 |
| Iida, A | 1 |
| Yamaguchi, A | 3 |
| Nakagawara, G | 1 |
| Umeda, S | 1 |
| Kusaka, Y | 1 |
| van der Vange, N | 1 |
| Kaag, MM | 3 |
| Beijnen, JH | 2 |
| Horsell, KW | 1 |
| Merten, S | 1 |
| Clingan, P | 1 |
| King, DW | 1 |
| Ohashi, M | 1 |
| Shimada, Y | 1 |
| Yamamoto, M | 1 |
| Nakajima, J | 1 |
| Hara, Y | 1 |
| Kawasaki, T | 1 |
| Yabata, E | 1 |
| Gen, T | 1 |
| Jibiki, M | 1 |
| Kudoh, A | 1 |
| Noguchi, N | 1 |
| Kataoka, T | 1 |
| Teramoto, K | 1 |
| Iwai, T | 1 |
| Samel, S | 1 |
| Singal, A | 1 |
| Becker, H | 1 |
| Post, S | 1 |
| Caillot, JL | 1 |
| Giannarelli, D | 2 |
| Botti, C | 2 |
| Cosimelli, M | 2 |
| Tedesco, M | 2 |
| Principi, F | 1 |
| Laurenzi, L | 2 |
| Cavaliere, R | 2 |
| Nakagami, K | 1 |
| Sugitani, K | 1 |
| Sasaki, T | 1 |
| Yokomori, T | 1 |
| Iesato, H | 1 |
| Ohya, T | 1 |
| Ohwada, S | 1 |
| Morishita, Y | 1 |
| Aloe, L | 1 |
| Arcuri, E | 1 |
| Aromatario, C | 1 |
| Consolo, S | 1 |
| Callopoli, A | 1 |
| Di Angelo, P | 1 |
| Giunta, S | 1 |
| Rey, Y | 1 |
| Porcheron, J | 1 |
| Talabard, JN | 1 |
| Szafnicki, K | 1 |
| Balique, JG | 1 |
| Pestieau, SR | 2 |
| Tanaka, T | 1 |
| Umesaki, N | 1 |
| Ogita, S | 1 |
| Noh, SH | 1 |
| Yoo, CH | 1 |
| Chung, HC | 1 |
| Roh, JK | 1 |
| Shin, DW | 1 |
| Min, JS | 1 |
| Rambo, TD | 1 |
| van Slooten, GW | 2 |
| van Coevorden, F | 2 |
| Yan, H | 1 |
| Shmookler, BM | 1 |
| Ikeguchi, M | 1 |
| Blot, F | 1 |
| El Otmany, A | 1 |
| Antoun, S | 1 |
| Lasser, P | 1 |
| Boige, V | 1 |
| Rougier, P | 1 |
| Ducreux, M | 1 |
| Chang, E | 1 |
| Alexander, HR | 1 |
| Libutti, SK | 1 |
| Hurst, R | 1 |
| Zhai, S | 1 |
| Figg, WD | 1 |
| Kuroki, Y | 1 |
| Otagiri, S | 1 |
| Tsukada, K | 1 |
| Kuhn, R | 1 |
| Halangk, W | 1 |
| Boltze, C | 1 |
| Kim, JY | 1 |
| Bae, HS | 1 |
| Akamo, Y | 1 |
| Takeyama, H | 1 |
| Teranishi, F | 1 |
| Manabe, T | 1 |
| Drees, J | 1 |
| Morris, RT | 1 |
| Sachs, D | 1 |
| Marchettini, P | 1 |
| Yachida, S | 1 |
| Fukushima, N | 1 |
| Sakamoto, M | 1 |
| Matsuno, Y | 1 |
| Kosuge, T | 1 |
| Hirohashi, S | 1 |
| Su, G | 1 |
| Qi, X | 1 |
| Ma, D | 1 |
| Fan, Y | 1 |
| Butterworth, SA | 1 |
| Panton, ON | 1 |
| Klaassen, DJ | 1 |
| Shah, AM | 1 |
| McGregor, GI | 1 |
| Murakami, M | 1 |
| Morikawa, A | 1 |
| Okabe, R | 1 |
| Hayashi, K | 1 |
| Miyazawa, K | 1 |
| Iijima, S | 1 |
| Suzuki, A | 1 |
| Koyama, Y | 1 |
| Sugiyama, A | 1 |
| Fujimoto, T | 1 |
| Zhang, B | 1 |
| Minami, S | 1 |
| Takahashi, Y | 1 |
| Mai, M | 1 |
| Ratto, C | 1 |
| Ricci, R | 1 |
| Rossi, C | 1 |
| Morelli, U | 1 |
| Vecchio, FM | 1 |
| Doglietto, GB | 1 |
| Tsukioka, Y | 1 |
| Kurosaka, Y | 1 |
| Kanno, M | 1 |
| Miyazaki, I | 1 |
| Nagano, K | 1 |
| Kure, M | 1 |
| Mutoh, T | 1 |
| Kodera, Y | 1 |
| Kondo, K | 1 |
| Nakahara, H | 1 |
| Nagai, S | 1 |
| Satta, T | 1 |
| Ito, K | 1 |
| Takagi, H | 1 |
| Chauffert, B | 1 |
| Dimanche-Boitrel, MT | 1 |
| Genne, P | 1 |
| Petit, JM | 1 |
| Onier, N | 1 |
| Jeannin, JF | 1 |
| Sudarshan, G | 1 |
| Crawford, D | 1 |
| Werner, A | 1 |
| Mallmann, P | 1 |
| Chronides, A | 1 |
| Diedrich, K | 1 |
| Wagner, U | 1 |
| Krebs, D | 1 |
| Takekawa, S | 1 |
| Ohoyama, S | 1 |
| Kimura, H | 1 |
| Kamata, T | 2 |
| Matsuki, N | 1 |
| Sawa, T | 1 |
| Sakuma, H | 1 |
| Fukuda, I | 1 |
| Imaoka, S | 1 |
| Masutani, S | 2 |
| Sasaki, Y | 2 |
| Kabuto, T | 2 |
| Furukawa, H | 2 |
| Koyama, H | 1 |
| Urade, M | 2 |
| Takegawa, S | 1 |
| Sugiyama, K | 2 |
| Hasegawa, H | 2 |
| Landy, D | 1 |
| Jaffe, G | 1 |
| Pascal, R | 1 |
| Shrestha, RD | 8 |
| Kokubun, M | 8 |
| Kiuchi, S | 7 |
| Konno, C | 6 |
| Okui, K | 7 |
| Hiratsuka, M | 1 |
| Iwanaga, T | 1 |
| Nagano, H | 1 |
| Oohigashi, H | 1 |
| Abe, T | 1 |
| Sasaki, M | 1 |
| Nakajima, H | 1 |
| Ogita, M | 1 |
| Naitou, H | 1 |
| Nagase, A | 1 |
| Taguchi, K | 1 |
| Miyazaki, S | 1 |
| Sugiyama, Y | 1 |
| Yoshida, A | 1 |
| Takao, H | 1 |
| Kunieda, K | 1 |
| Miya, K | 1 |
| Azuma, S | 1 |
| Tanemura, H | 1 |
| Furuta, T | 1 |
| Saji, S | 1 |
| Takashima, S | 1 |
| Doihara, H | 1 |
| Yokoyama, N | 1 |
| Tanada, M | 1 |
| Soga, H | 1 |
| Kurita, A | 1 |
| Takiyama, W | 1 |
| Saeki, H | 1 |
| Moriwaki, S | 1 |
| Ohta, M | 6 |
| Graves, T | 1 |
| DeBruijn, EA | 1 |
| Cunliffe, WJ | 1 |
| Mullins, RE | 1 |
| Hull, WE | 1 |
| Oliff, L | 1 |
| Schlag, P | 1 |
| Nagashima, K | 1 |
| Kimura, K | 1 |
| Koyanagi, Y | 1 |
| Kusama, K | 1 |
| Ono, M | 1 |
| Nakajima, A | 1 |
| Eiraku, H | 1 |
| Serizawa, H | 1 |
| Ebihara, Y | 1 |
| Kuwahara, A | 1 |
| Hirao, E | 1 |
| Shimoda, K | 1 |
| Yoshida, T | 1 |
| Miyahara, M | 1 |
| Saito, T | 1 |
| Kobayashi, M | 1 |
| Sawai, K | 1 |
| Iwamoto, A | 2 |
| Yoneyama, C | 2 |
| Kitsukawa, Y | 1 |
| Iitsuka, Y | 1 |
| Kikuchi, S | 1 |
| Sasabe, T | 1 |
| Itoh, M | 1 |
| Kondoh, S | 1 |
| Seiki, K | 1 |
| Hashimoto, T | 1 |
| Miyata, R | 1 |
| Matsuda, Y | 1 |
| Hayashi, T | 1 |
| Nasu, Y | 1 |
| Aramaki, K | 1 |
| Johsen, T | 1 |
| Matsuura, H | 1 |
| Lee, R | 3 |
| Ueda, T | 3 |
| Takeda, M | 3 |
| Itoh, T | 3 |
| Murakami, A | 1 |
| Wakatsuki, T | 1 |
| Miyoshi, T | 1 |
| Arimizu, N | 1 |
| Monk, BJ | 1 |
| Surwit, EA | 1 |
| Alberts, DS | 1 |
| Graham, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial to Analyze Clinical and Pharmacological Properties for Severe Neutropenia After Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy Using Mitomycin-C[NCT05513183] | 74 participants (Actual) | Observational | 2021-05-20 | Completed | |||
| Comparative Study on the Efficacy of Mitomycin and Lobaplatin in the Treatment of Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy[NCT04845490] | Phase 2 | 201 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Recurrence in Patients With High-risk Colorectal and Appendiceal Neoplasms : a Pilot Study[NCT05623787] | 30 participants (Anticipated) | Interventional | 2022-09-01 | Recruiting | |||
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Systemic Chemotherapy Versus Systemic Chemotherapy Alone as 1st-line Treatment of Malignant Peritoneal Mesothelioma[NCT03875144] | Phase 2 | 66 participants (Anticipated) | Interventional | 2020-08-14 | Recruiting | ||
| BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410] | Phase 2 | 60 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Thrombin Generation and Platelet Activation in Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy[NCT03034850] | 27 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| To Study the Changes in Coagulation Profile in Patients Undergoing CRS(CYTOREDUCTIVE SURGERY) and HIPEC(HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY)[NCT03137745] | 60 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial[NCT00454519] | Phase 2 | 60 participants (Anticipated) | Interventional | 2007-03-31 | Recruiting | ||
| A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis[NCT05648487] | Phase 2 | 46 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | ||
| Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy[NCT02741167] | 90 participants (Anticipated) | Observational | 2016-01-31 | Recruiting | |||
| A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer[NCT01376752] | Phase 3 | 415 participants (Actual) | Interventional | 2011-04-26 | Active, not recruiting | ||
| D2 Radical Resection After Neoadjuvant Chemotherapy Combined With HIPEC for Advanced Gastric Cancer: a Prospective Randomized Controlled Trial[NCT02960061] | Phase 3 | 640 participants (Anticipated) | Interventional | 2016-11-30 | Not yet recruiting | ||
| A Prospective, Multicentral, Open-label, Randomized, Controlled Clinical Trial to Investigation the Value of Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer[NCT02745509] | 508 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Comparative Study on the Efficacy of Lobaplatin and Paclitaxel in the Treatment of Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy[NCT04808466] | Phase 2 | 231 participants (Anticipated) | Interventional | 2021-09-18 | Recruiting | ||
| Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding[NCT00539877] | Phase 1 | 17 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094] | Phase 3 | 49 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)[NCT05913674] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | ||
| Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis[NCT00001569] | Phase 1 | 74 participants | Interventional | 1997-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for mitomycin and Peritoneal Neoplasms
| Article | Year |
|---|---|
After thirty years of experience with early postoperative intraperitoneal 5-fluorouracil now saying goodbye.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2022 |
Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Proce | 2019 |
Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Proce | 2020 |
Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review.
Topics: Appendiceal Neoplasms; Cytoreduction Surgical Procedures; Humans; Hyperthermia, Induced; Mitomycin; | 2020 |
Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Proto | 2021 |
Pseudomyxoma Peritonei: Case Report and Literature Review.
Topics: Appendiceal Neoplasms; Appendix; Biopsy; Colectomy; Combined Modality Therapy; Cytoreduction Surgica | 2019 |
Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
Topics: Antibiotics, Antineoplastic; Appendiceal Neoplasms; Australia; Chemotherapy, Cancer, Regional Perfus | 2019 |
[Peritoneal tumor pathology: case n(o) 2: a "sticky" peritoneal tumor].
Topics: Abdominal Pain; Adult; Antineoplastic Agents, Alkylating; Appendectomy; Appendiceal Neoplasms; Combi | 2015 |
Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hu | 2012 |
Pharmacokinetics of intraperitoneal mitomycin C.
Topics: Area Under Curve; Biological Availability; Carcinoma; Chemotherapy, Adjuvant; Dose-Response Relation | 2003 |
Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Gastro | 2004 |
Pharmacokinetics of the antineoplastic drug mitomycin C in regional chemotherapy using the aortic stop flow technique in advanced pancreatic carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Area Under Curve; Biological Availability; Chemotherapy, C | 2005 |
Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Combined Modality Therapy; Fl | 2006 |
Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxorubicin; Female; Fluor | 2005 |
A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 2006 |
Comprehensive management of diffuse malignant peritoneal mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; H | 2006 |
Management of pseudomyxoma peritonei.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Doxorubicin; Humans; Hyperthermia, Indu | 2006 |
[Mechanism of neoplasm metastasis and treatment strategy].
Topics: Humans; Immunotoxins; Mitomycin; Neoplasm Invasiveness; Neoplasm Metastasis; Peritoneal Neoplasms; S | 1995 |
[Prophylaxis and treatment of peritoneal metastasis from gastric cancer].
Topics: Gastrectomy; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Mitomycin; Peritoneal Neopl | 1996 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cis | 1998 |
[Chemo-hyperthermic peritoneal perfusion for therapy of advanced gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Humans; Hyperthermia, In | 2001 |
Mucinous adenocarcinoma of the small bowel with peritoneal seeding.
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Management of peritoneal carcinomatosis.
Topics: Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Injections, Intra | 1989 |
71 trials available for mitomycin and Peritoneal Neoplasms
| Article | Year |
|---|---|
Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthe | 2022 |
Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Appendiceal Neoplas | 2020 |
Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Cisplatin; Combined M | 2020 |
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cap | 2021 |
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduc | 2021 |
Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Feasibility | 2013 |
Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Colorectal Neo | 2014 |
Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Cancer, Regional Perf | 2015 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; China; Cisplatin; | 2014 |
Routine second-look after surgical treatment of colonic peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemo | 2015 |
A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antige | 2008 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2009 |
Phase II study of regional treatment for peritoneal carcinomatosis.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Chemotherapy, Cancer, R | 2009 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2010 |
Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; | 2011 |
Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clin | 2011 |
Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2011 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Feasibility of delayed hyperthermic intraperitoneal chemotherapy in case of unforeseen complications.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2011 |
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Chemoth | 2013 |
A phase I trial of thermal sensitization using induced oxidative stress in the context of HIPEC.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Carcinoma; Colonic Neoplasms; Female; Hum | 2013 |
Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
[Effectiveness of continuous hyperthermic peritoneal perfusion for the peritoneal dissemination of gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisp | 2002 |
Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis.
Topics: Antibiotics, Antineoplastic; Carcinoma; Combined Modality Therapy; Female; Humans; Hyperthermia, Ind | 2003 |
Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2003 |
Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Differe | 2003 |
Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer.
Topics: Adult; Aged; Biopsy, Needle; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Combined Modality | 2004 |
Long-term survival of peritoneal carcinomatosis of colorectal origin.
Topics: Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Fol | 2005 |
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2005 |
Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Area Under Curve; Chemotherapy, Cancer, Regional Perfusion | 2005 |
Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Cancer, Regio | 2006 |
Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2006 |
An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with pseudomyxoma peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2003 |
An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2003 |
Sitilo experience on peritoneal carcinomatosis from colorectal cancer: clinical prognostic features.
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Colorectal Neoplasms; Combined Mod | 2003 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2006 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Combined Chemo | 2006 |
Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Female; Hospitalization; Humans; Hyperthermi | 2006 |
Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis.
Topics: Adult; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Parente | 2007 |
Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Humans; Hy | 2008 |
Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adju | 2008 |
[Evaluation of intraoperative peritoneal cytology and intraperitoneal chemotherapy using CDDP combined with MMC for gastric carcinomatous peritonitis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Female; Human | 1995 |
Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy.
Topics: Absorption; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chromatog | 1994 |
Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendicea | 1995 |
[The prevention of peritoneal dissemination of gastric cancer with intraperitoneal activated carbon particles absorbing mitomycin C].
Topics: Absorption; Carbon; Female; Humans; Infusions, Parenteral; Lymphatic Metastasis; Male; Middle Aged; | 1994 |
[Evaluation of intraperitoneal chemotherapy using CDDP combined with MMC in gastric carcinomatous peritonitis].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fe | 1994 |
Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modali | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1994 |
Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy.
Topics: Antibiotics, Antineoplastic; Ascites; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; | 1997 |
Continuous hyperthermic peritoneal perfusion for peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 1996 |
Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Female; Gastrointes | 1997 |
Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Charcoal; Chemotherapy, Adjuvant; Disease-Free Su | 1998 |
Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Charcoal; Chemotherapy, Adjuvant; Disease-Free Su | 1998 |
Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Charcoal; Chemotherapy, Adjuvant; Disease-Free Su | 1998 |
Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Charcoal; Chemotherapy, Adjuvant; Disease-Free Su | 1998 |
[Results of intraperitoneal active charcoal-mitomycin C therapy of stomach carcinoma with serosa invasion].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Charcoal; Chemotherapy, Cancer, Regional P | 1998 |
Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1999 |
[Repeated intraperitoneal chemotherapy for peritoneal dissemination from gastric carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; Humans; Infusio | 1999 |
Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Combined Modality Therapy; Equipment Design; Fe | 2000 |
[Peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemohyperthermia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; | 2000 |
Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic N | 2000 |
Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; | 2001 |
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2001 |
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Ne | 2001 |
Laparoscopic continuous hyperthermic peritoneal perfusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chemotherapy, Cancer, | 2001 |
[Repeated intraperitoneal chemotherapy for peritoneal dissemination from gastric carcinoma].
Topics: Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Humans; Infusion Pumps, Implantable; | 2001 |
A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP).
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2001 |
Local injection of M-CH combined with i.p. hyperthermic hypo-osmolar infusion is an effective therapy in advanced gastric cancer.
Topics: Adenocarcinoma; Charcoal; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Injectio | 2002 |
Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin C for patients with gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Ascitic Fluid; Combined Modality Therapy; Female; Histocytochemistry; Humans; Hyperther | 1992 |
[Intraperitoneal administration of recombinant interferon-beta for prevention in peritoneal metastasis of gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastrectomy; Huma | 1990 |
Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer.
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials as Topic; Combined Modality Therapy | 1989 |
Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Clinical trials.
Topics: Charcoal; Clinical Trials as Topic; Dosage Forms; Female; Humans; Microscopy, Electron; Middle Aged; | 1987 |
Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C.
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Drug Evaluation; Female; Humans; Hyperthermia, Indu | 1988 |
311 other studies available for mitomycin and Peritoneal Neoplasms
| Article | Year |
|---|---|
Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthe | 2022 |
ASO Author Reflections: Delayed Occurrence and Postoperative Risks of Mitomycin-C-Induced Neutropenia After Hyperthermic Intraperitoneal Chemotherapy.
Topics: Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthermia, Induced; Hyperth | 2022 |
Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients.
Topics: Adult; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermic Intrape | 2022 |
Cytoreductive surgery and concomitant hyperthermic thoracoabdominal chemotherapy for pseudomyxoma peritonei with abdominal and pleural involvement.
Topics: Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthermia, Induced; Mitomyc | 2022 |
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; | 2022 |
Safety of Nephrectomy Performed During CRS/HIPEC: A Propensity Score-Matched Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytoreduction Surgical Pr | 2023 |
Safety of Nephrectomy Performed During CRS/HIPEC: A Propensity Score-Matched Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytoreduction Surgical Pr | 2023 |
Safety of Nephrectomy Performed During CRS/HIPEC: A Propensity Score-Matched Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytoreduction Surgical Pr | 2023 |
Safety of Nephrectomy Performed During CRS/HIPEC: A Propensity Score-Matched Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytoreduction Surgical Pr | 2023 |
Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2023 |
Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2023 |
Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2023 |
Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2023 |
Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colorectal | 2023 |
Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colorectal | 2023 |
Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colorectal | 2023 |
Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colorectal | 2023 |
PD-1 Blockade Combined with Heated Intraperitoneal Chemotherapy Improves Outcome in Experimental Peritoneal Metastases from Colonic Origin in a Murine Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality The | 2023 |
Immunological effects of heated intraperitoneal chemotherapy can be augmented by thymosin α1.
Topics: Animals; Colorectal Neoplasms; Combined Modality Therapy; Hyperthermia, Induced; Mice; Mitomycin; Ne | 2023 |
Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching A
Topics: Colonic Neoplasms; Combined Modality Therapy; Humans; Hyperthermia, Induced; Hyperthermic Intraperit | 2023 |
Open versus Closed technique for administration of heated intraperitoneal chemotherapy (HIPEC): Morbidity and Mortality outcomes from a high-volume centre.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2023 |
Treating colorectal peritoneal metastases with an injectable cytostatic loaded supramolecular hydrogel in a rodent animal model.
Topics: Animals; Colonic Neoplasms; Colorectal Neoplasms; Cytostatic Agents; Hydrogels; Mitomycin; Peritonea | 2023 |
Cisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Humans; Hypert | 2023 |
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin.
Topics: Appendiceal Neoplasms; Bevacizumab; Capecitabine; Disease Progression; Humans; Hyperthermia, Induced | 2023 |
2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Con | 2024 |
Evaluation and management of toxicity of cytoreductive surgery/hyperthermic intraperitoneal chemotherapy: the initial experience of a single centre study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2020 |
Beware mis-representation of PRODIGE 7: danger of throwing out the cytoreductive surgery baby with the hyperthermic intraperitoneal chemotherapy bathwater.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Australia; Carcinoma, Ovarian Epithelia | 2019 |
Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei.
Topics: Animals; Antibiotics, Antineoplastic; Combined Modality Therapy; Cystadenocarcinoma, Mucinous; Cytor | 2019 |
Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neop | 2020 |
Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Chemot | 2020 |
Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthe | 2020 |
Cytoreductive Surgery and HIPEC in an Enhanced Recovery After Surgery Program: A Feasibility Study.
Topics: Acute Kidney Injury; Adult; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Cytoreduction Surgi | 2020 |
Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Cytoreduction Surgical Procedure | 2020 |
Effect of intraperitoneal chemotherapy concentration on morbidity and survival.
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Dat | 2020 |
Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasm | 2020 |
shRNA-mediated inhibition of PhosphoGlycerate Kinase 1 (PGK1) enhances cytotoxicity of intraperitoneal chemotherapy in peritoneal metastasis of gastric origin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorou | 2020 |
Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases.
Topics: Acute Kidney Injury; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2020 |
Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedur | 2020 |
Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents; Colorectal Neoplasms; Cytored | 2020 |
Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases.
Topics: Aged; Alleles; Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Cytochrome P-450 Enzyme | 2020 |
Peritoneal carcinomatosis of unknown primary site, a study of 25 patients over 30 years.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; | 2020 |
Feasibility of diaphragmatic interventions in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: A 20-year experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chest Tubes; Cisplatin; Combined Modality Therapy; C | 2021 |
Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI).
Topics: Aged; Cisplatin; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; | 2021 |
Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Colorectal Neoplasms; Drug | 2021 |
Mode of Presentation in 1070 Patients With Perforated Epithelial Appendiceal Tumors, Predominantly with Pseudomyxoma Peritonei.
Topics: Adenocarcinoma, Mucinous; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Appendicitis; Bi | 2020 |
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Colonic Neoplasms; Cy | 2021 |
Intraperitoneal collagenase as a novel therapeutic approach in an experimental model of colorectal peritoneal carcinomatosis.
Topics: Animals; Antibiotics, Antineoplastic; Carcinoma; Collagenases; Colorectal Neoplasms; Disease Models, | 2021 |
Individual learning curve of cytoreductive surgery for peritoneal metastasis from colorectal cancer: A process with an impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cholecystectomy; Colectomy; | 2021 |
Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Colorectal Neoplasms; Female; Humans; Hyp | 2021 |
Exploring the prognostic and therapeutic utility of expanded mutation profiling in appendix peritoneal metastasis managed with CRS/HIPEC.
Topics: Adult; Aged; Aged, 80 and over; Appendiceal Neoplasms; Combined Modality Therapy; Cytoreduction Surg | 2021 |
10 ns PEFs induce a histological response linked to cell death and cytotoxic T-lymphocytes in an immunocompetent mouse model of peritoneal metastasis.
Topics: Animals; Antibiotics, Antineoplastic; Cell Death; Colorectal Neoplasms; Combined Modality Therapy; D | 2021 |
Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Cytoreduction Surgical Procedures; Doxorubicin; Femal | 2021 |
Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; Colorectal Neoplasms; Combined Modal | 2021 |
Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction S | 2021 |
Delayed genital necrosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with Mitomycin-C.
Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Combined Modality Therapy; Cytoreduction Surgica | 2021 |
The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI).
Topics: Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthe | 2021 |
Pancytopenia after administration of hyperthermic intraperitoneal chemotherapy with mitomycin-C: local therapy and systemic toxicity.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hyperthermic Intraperitoneal Chemotherapy; Mitomycin; P | 2021 |
Starting a peritoneal carcinomatosis treatment program in a developing country: A prospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional Perfusio | 2021 |
Haemodynamic changes during hyperthermic intra-thoracic chemotherapy for pseudomyxoma peritonei.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Cytoreduction Surgical Procedur | 2017 |
Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Topics: Acid-Base Imbalance; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytoreduction | 2017 |
Antimicrobial Properties of Perfusate Fluid After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CS-HIPEC) with Mitomycin C.
Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Combin | 2017 |
Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Che | 2017 |
Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey.
Topics: Antineoplastic Agents; Carcinoma; Cardiac Output; Cisplatin; Colorectal Neoplasms; Cytoreduction Sur | 2018 |
Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cohort Studies; Colorectal Neoplasms; Combined Modality Ther | 2018 |
CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Carcinoma; Cohort St | 2018 |
Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; | 2018 |
A Modified Low-Cost Technique of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Two Patients: a Solution for Pseudomyxoma Peritonei in the Indian Scenario?
Topics: Adult; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, I | 2019 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report.
Topics: Antineoplastic Agents, Alkylating; Bile Duct Neoplasms; Cholangiocarcinoma; Cholangitis, Sclerosing; | 2018 |
Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Fem | 2018 |
Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent.
Topics: Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Su | 2018 |
Comparing the cytotoxicity of taurolidine, mitomycin C, and oxaliplatin on the proliferation of in vitro colon carcinoma cells following pressurized intra-peritoneal aerosol chemotherapy (PIPAC).
Topics: Aerosols; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colonic Neo | 2019 |
Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Hyperthermia, | 2019 |
A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality | 2019 |
Assessment of neoadjuvant chemotherapy on operative parameters and outcome in patients with peritoneal dissemination from high-grade appendiceal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Carcinoma; Colorectal Neoplasms; Co | 2013 |
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies.
Topics: ADP Ribose Transferases; Animals; Antigens, Neoplasm; Bacterial Toxins; Cell Adhesion Molecules; Dis | 2013 |
Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma; Cisplatin; Combined Modality Ther | 2013 |
Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei.
Topics: Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Carcinoembryonic Antigen; | 2013 |
Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2013 |
Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Appendic | 2013 |
Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2013 |
Controversy and consensus on the management of patients with pseudomyxoma peritonei.
Topics: Carcinoma; Combined Modality Therapy; Diagnosis, Differential; Humans; Mitomycin; Neoplasm Staging; | 2013 |
Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Carboplatin; Car | 2013 |
Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Hypert | 2013 |
Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; | 2014 |
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Stu | 2014 |
The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Blood Loss, Surgical; Chemotherapy, Ca | 2014 |
Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplast | 2014 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusio | 2014 |
Can hyperthermic intraperitoneal chemotherapy efficiency be improved by blocking the DNA repair factor COP9 signalosome?
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; COP9 Signalosome Complex; Curcumin; DNA Damage; Enzyme | 2014 |
Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 2014 |
Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Female; | 2014 |
Evaluation of a new staging classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 229 patients with mucinous appendiceal neoplasms with or without peritoneal dissemination.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Alkylating Agents; Appendectomy; Appendiceal Neoplasms; Chemo | 2014 |
Rapamycin-enhanced mitomycin C-induced apoptotic death is mediated through the S6K1-Bad-Bak pathway in peritoneal carcinomatosis.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Apoptosis; bcl-2 Homologous Antagonist-Killer | 2014 |
Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combin | 2014 |
Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Colorec | 2014 |
The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Colore | 2014 |
[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin].
Topics: Antibiotics, Antineoplastic; Antineoplastic Protocols; Appendiceal Neoplasms; Carcinoma; Chemotherap | 2014 |
Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Appendiceal Neoplas | 2015 |
Scrotal pain and ulceration post HIPEC: a case report.
Topics: Adult; Cytoreduction Surgical Procedures; Gastrointestinal Neoplasms; Genital Diseases, Male; Humans | 2015 |
Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 2014 |
Utility of Chemoresponse Assay in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytoreductio | 2015 |
Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CDX2 Transcri | 2015 |
Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Chemother | 2015 |
Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival.
Topics: Antibiotics, Antineoplastic; Biomarkers, Tumor; Caco-2 Cells; Cell Line, Tumor; Colorectal Neoplasms | 2015 |
Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Blood Loss, Surgical; Colorectal Neoplasms; Cytoreduction Surgical Proc | 2015 |
The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Cisplatin; Colorectal Neoplas | 2015 |
Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferati | 2015 |
Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2015 |
Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Prolifera | 2015 |
Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Cisplatin; Cohort Studies; C | 2015 |
Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy P | 2016 |
Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Canc | 2016 |
Cytoreduction and hyperthermic intraperitoneal chemotherapy: The learning curve reassessed.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; | 2016 |
Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option.
Topics: Adult; Aged; Analgesia, Epidural; Antineoplastic Agents; Blood Coagulation; Cisplatin; Combined Moda | 2015 |
Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option.
Topics: Adult; Aged; Analgesia, Epidural; Antineoplastic Agents; Blood Coagulation; Cisplatin; Combined Moda | 2015 |
Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option.
Topics: Adult; Aged; Analgesia, Epidural; Antineoplastic Agents; Blood Coagulation; Cisplatin; Combined Moda | 2015 |
Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option.
Topics: Adult; Aged; Analgesia, Epidural; Antineoplastic Agents; Blood Coagulation; Cisplatin; Combined Moda | 2015 |
[Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophos | 2015 |
Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 2016 |
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; China; | 2016 |
Favorable response to an endothelin receptor antagonist in mitomycin-induced pulmonary veno-occlusive disease with pulmonary capillary hemangiomatosis.
Topics: Aged; Endothelin Receptor Antagonists; Fatal Outcome; Female; Hemangioma, Capillary; Humans; Mitomyc | 2016 |
Prophylactic hyperthermic intraperitoneal chemotherapy in patients with epithelial appendiceal neoplasms.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Chemotherapy, Cancer, Regional Perf | 2016 |
Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduc | 2016 |
Digital Glissonectomy: A Safe Perihepatic Peritonectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2016 |
Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes.
Topics: Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; CA-125 Antigen; CA-19-9 Antigen; Carcinoem | 2016 |
Surgical Treatment of Colorectal Cancer with Peritoneal and Liver Metastases Using Combined Liver and Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Report from a Single-Centre Experience.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Catheter Ablation; Colo | 2016 |
Outcome and surgical strategy in critical sites in cases of psuedomyxoma peritonei.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytoreduction Surg | 2016 |
Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; | 2017 |
Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes.
Topics: Adenocarcinoma; Adult; Aged; Body Mass Index; Chemotherapy, Cancer, Regional Perfusion; Colonic Neop | 2017 |
Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution's Experience During Two Decades.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2017 |
Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colorectal Neoplasms; Combined | 2016 |
Management of an inguinal hernia in patients with pseudomyxoma peritonei.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2017 |
Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Cancer, | 2017 |
The effects of hyperthermic intraperitoneal chemoperfusion on colonic anastomosis: an experimental study in a rat model.
Topics: Anastomosis, Surgical; Animals; Chemotherapy, Adjuvant; Cisplatin; Colorectal Neoplasms; Combined Mo | 2017 |
The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat.
Topics: Abdominal Wall; Anastomosis, Surgical; Animals; Antibiotics, Antineoplastic; Chemotherapy, Cancer, R | 2008 |
Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Mo | 2009 |
Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Camptothecin; C | 2009 |
Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, P | 2009 |
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2009 |
Sugarbaker procedure for pseudomyxoma peritonei.
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Digestive System Surgical Procedures; Humans | 2009 |
[Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel].
Topics: Air Pollutants, Occupational; Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Cancer, | 2009 |
Simultaneous bicavitary hyperthermic chemoperfusion in the management of pseudomyxoma peritonei with synchronous pleural extension.
Topics: Antibiotics, Antineoplastic; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Ag | 2009 |
Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasm | 2010 |
Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Topics: Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combine | 2010 |
Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; France; Humans; H | 2010 |
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2010 |
Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2010 |
Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation.
Topics: Adult; Antineoplastic Agents; Cell Differentiation; Cell Transformation, Neoplastic; Disease Progres | 2010 |
Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; H | 2010 |
Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings.
Topics: Antibiotics, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Stud | 2011 |
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ap | 2011 |
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Endometrial Neopl | 2010 |
Hepatobiliary procedures in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Diseases; Chemotherapy, Cancer, Regional P | 2011 |
[Successful treatment of multiple pulmonary and peritoneal recurrence of hepatocellular carcinoma with bronchial artery infusion therapy and PEIT followed by surgery--a case report].
Topics: Aged, 80 and over; Antineoplastic Agents; Bronchial Arteries; Carcinoma, Hepatocellular; Ethanol; He | 2010 |
Childbearing after hyperthermic intraperitoneal chemotherapy: results from an international survey.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Pe | 2011 |
Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Cancer, Regi | 2011 |
Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Humans; Hyperthermia, Induced; Mito | 2011 |
Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic | 2012 |
Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blood | 2012 |
Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2011 |
Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2012 |
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis secondary to urachal adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy | 2012 |
Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms.
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Disease-Free Survival; | 2012 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovari | 2012 |
HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome?
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Chemotherapy, C | 2012 |
Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2013 |
HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Ascites and malnutrition are predictive factors for incomplete cytoreductive surgery for peritoneal carcinomatosis from gastric cancer.
Topics: Antibiotics, Antineoplastic; Ascites; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Hype | 2013 |
Aggressive locoregional management of recurrent peritoneal sarcomatosis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2013 |
[Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2002 |
Intraoperative modality of treatment for peritoneal carcinomatosis: use of hyperthermic interperitoneal chemoperfusion.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Combined Modality Therapy; Female; | 2002 |
Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.
Topics: Activities of Daily Living; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma; Chemotherapy, Cance | 2003 |
Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2003 |
Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Agents; Area Under Curve; Biol | 2003 |
Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasm | 2003 |
Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Com | 2003 |
Detection and treatment of the micrometastases of gastric cancer.
Topics: Carcinoembryonic Antigen; Humans; Mitomycin; Peritoneal Neoplasms; Stomach Neoplasms | 2004 |
Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative chemotherapy in advanced gastric carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; C | 2004 |
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.
Topics: Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Disease-Fre | 2004 |
Fatal arrhythmia following intraoperative continuous hyperthermic peritoneal perfusion chemotherapy.
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, | 2003 |
Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Middle Aged; M | 2004 |
[The Czech experience in peritonectomy and hyperthermic perioperative cytostatic lavage in the treatment of peritoneal malignancy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Cancer, Regi | 2004 |
Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 2004 |
[Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2004 |
[A case of advanced gastric cancer with peritonitis carcinomatosa resected with intraperitoneal chemotherapy based on chemosensitivity test with ascites].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; Drug Administrati | 2004 |
Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2005 |
[Intraperitoneal chemotherapy against peritoneal carcinomatosis of gastric cancer with activated carbon particles adsorbing mitomycin C for four patients].
Topics: Adsorption; Aged; Antibiotics, Antineoplastic; Ascites; Biomarkers, Tumor; Charcoal; Dosage Forms; F | 2004 |
Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61-67.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Color | 2004 |
Treatment of peritoneal carcinomatosis in patients with digestive cancers with combination of intraperitoneal hyperthermia and mitomycin C.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Ascites; Carcinoma; Combined Modality Therapy; Female; Gas | 2004 |
Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Female; Health Status; Hum | 2005 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant mixed mesodermal tumours with peritoneal dissemination.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2005 |
Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2005 |
[Anaesthesiologic problems about hyperthermic intraoperative intraperitoneal chemotherapy].
Topics: Adult; Anesthesia; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Female; Hemodynami | 2004 |
Lymph node metastasis in epithelial malignancies of the appendix with peritoneal dissemination does not reduce survival in patients treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Combine | 2005 |
Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2005 |
A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis.
Topics: Animals; Body Weight; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug; | 2005 |
Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Carcin | 2005 |
[Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Color | 2005 |
Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Area Under Curve; Ascitic Fluid; Body Surface | 2006 |
An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Cisplatin; Containment of Bio | 2005 |
Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Combined | 2006 |
[Effectiveness of intraperitoneal chemotherapy using new-aged drugs for the peritoneal dissemination of gastric cancer].
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Humans; Infusions, Parenteral; Mitomyci | 2005 |
[A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2006 |
Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2006 |
Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2006 |
Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C.
Topics: Air Pollutants, Occupational; Antibiotics, Antineoplastic; Chromatography, High Pressure Liquid; Com | 2006 |
Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Chemotherapy, Cancer, Regi | 2006 |
Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplas | 2007 |
[Anesthetic management for scheduled peritonectomy and hyperthermic intraperitoneal chemotherapy in 20 patients].
Topics: Adult; Aged; Analgesia, Epidural; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intraveno | 2006 |
Intraoperative hyperthermic intrathoracic chemotherapy for pleural extension of pseudomyxoma peritonei.
Topics: Adult; Anesthesia, General; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemothera | 2007 |
Interstitial pneumonitis: an exceptional toxicity of hyperthermic intraperitoneal mitomycin C.
Topics: Antibiotics, Antineoplastic; Appendiceal Neoplasms; Female; Humans; Hyperthermia, Induced; Infusions | 2008 |
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures.
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infus | 2007 |
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Chemothe | 2007 |
Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; | 2007 |
Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Appen | 2007 |
Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2007 |
Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.
Topics: Camptothecin; Cisplatin; Cytotoxins; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; H | 2008 |
A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Body Weight; Colonic Neoplasms; Combin | 2007 |
Hyperthermic intraperitoneal chemoperfusion is an option for treatment of peritoneal carcinomatosis in children.
Topics: Antibiotics, Antineoplastic; Carcinoma, Signet Ring Cell; Chemotherapy, Cancer, Regional Perfusion; | 2007 |
Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2007 |
[New treatment of peritoneal carcinomatosis from colorectal cancer. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
Topics: Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy | 2007 |
Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplas | 2008 |
Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Biomarker | 2008 |
Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience.
Topics: Antineoplastic Agents; Carcinoma; Cisplatin; Drug Therapy, Combination; Female; Follow-Up Studies; F | 2008 |
Sirolimus and intraoperative hyperthermic peritoneal chemoperfusion with mitomycin-C do not impair healing of bowel anastomoses.
Topics: Anastomosis, Surgical; Animals; Antibiotics, Antineoplastic; Cell Proliferation; Digestive System Ne | 2008 |
"Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drainage; | 2009 |
F-18 FDG PET-CT findings of intraperitoneal carbon particles-induced granulomas mimicking peritoneal carcinomatosis.
Topics: Adult; Carbon; Diagnosis, Differential; Extravasation of Diagnostic and Therapeutic Materials; False | 2008 |
[Serum levels of mitomycin C following a high-dose continuous hyperthermic peritoneal perfusion].
Topics: Female; Hot Temperature; Humans; Lung Neoplasms; Mitomycin; Mitomycins; Ovarian Neoplasms; Perfusion | 1984 |
[Experimental studies on continuous hyperthermic peritoneal perfusion in the treatment for peritoneal metastases of cancer].
Topics: Animals; Antibiotics, Antineoplastic; Cell Survival; Cells, Cultured; Combined Modality Therapy; Hyp | 1983 |
[Constant intra-aortic infusion chemotherapy for advanced abdominal cancer--a technic and the effect in patients with peritoneal metastases].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Coloni | 1984 |
Scintigraphic peritoneography in advanced ovarian malignancies: its value for chemotherapeutic distribution studies.
Topics: Adult; Aged; Catheterization; Female; Humans; Infusions, Parenteral; Middle Aged; Mitomycin; Mitomyc | 1984 |
FAM2 regimen in disseminated gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1984 |
[Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined | 1995 |
Preoperative intraperitoneal chemotherapy for gastric cancer, with special reference to delayed peritoneal complications.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1995 |
Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Chemotherapy, Cancer, Regional Perfusion; Combine | 1994 |
Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Doxoru | 1994 |
[Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data].
Topics: Aged; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Inject | 1993 |
[Intraperitoneal repeated chemotherapy using CDDP combined with MMC for carcinomatous peritonitis].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 1993 |
[Four long-surviving cases of gastric cancer with peritoneal dissemination treated by intraperitoneal administration of mitomycin C adsorbed on activated carbon particles].
Topics: Adenocarcinoma; Adult; Aged; Carbon; Chemotherapy, Adjuvant; Delayed-Action Preparations; Female; Ga | 1993 |
Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases.
Topics: Antibiotics, Antineoplastic; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Chemotherapy, Cancer, | 1996 |
Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Female; Gastrointestinal Neopla | 1996 |
Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Appendiceal Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans | 1996 |
Mechanism and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to carbon particles.
Topics: Antibiotics, Antineoplastic; Carbon; Female; Humans; Injections, Intraperitoneal; Male; Middle Aged; | 1996 |
Heated intraperitoneal mitomycin C infusion treatment for patients with gastric cancer and peritoneal metastasis.
Topics: Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Humans; Hyperthermia, Induced | 1996 |
Peritoneal carcinomatosis and radioimmunoguided surgery.
Topics: Antibiotics, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality Thera | 1996 |
Complications of heated intraperitioneal chemotherapy and strategies for prevention.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Female; Humans; Hyperthermia, Induced; Male; Middle Aged; | 1996 |
Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Colonic Neoplasms; Female; Fluorouracil; | 1996 |
[A case of gastric cancer with peritoneal dissemination and malignant biliary stenosis treated by loco-regional cancer therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Cisplatin; Combined Modality Ther | 1996 |
[Two cases of pseudomyxoma peritonei that responded to intraperitoneal administrations of a combined CDDP, 5-FU and MMC therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administrati | 1996 |
Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin.
Topics: Abdomen; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, | 1996 |
Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery.
Topics: Carcinoma; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Male; Middle Aged; Mito | 1997 |
[Study of the toxicity and results of intraperitoneal hyperthermic chemotherapy in 28 patients with peritoneal carcinomatosis].
Topics: Abdominal Neoplasms; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Female; Humans; Hyperther | 1997 |
[Evaluation of intraperitoneal chemotherapy using CDDP/MMC or CDDP for gastric carcinomatous peritonitis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Humans; Inf | 1997 |
[Effect of preoperative THP-FLPM (pirarubicin, 5-fluorouracil, leucovorin, cisplatin, mitomycin C) therapy on far advanced gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxo | 1998 |
[A CR case of amylase-producing tumor treated by hyperthermochemotherapy].
Topics: Adenocarcinoma; Amylases; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Floxu | 1998 |
[Clinical result of intraperitoneal hyperthermic chemoperfusion for gastric cancer with serosal invasion to prevent peritoneal recurrence].
Topics: Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Hyperthermia, | 1998 |
[Perspectives in the treatment of peritoneal carcinosis].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1997 |
[Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Ascites; Carcinoma; Cause of Death; Chemotherapy, Cancer, | 1997 |
Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice.
Topics: Acetamides; Animals; Antineoplastic Agents; Cisplatin; Gelatinases; Humans; Male; Matrix Metalloprot | 1999 |
Therapy of pseudomyxoma peritonei of appendiceal origin--surgical resection and intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Ad | 1999 |
[Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute].
Topics: Antibiotics, Antineoplastic; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Dose-Response R | 1999 |
Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer.
Topics: Abscess; Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 1999 |
[Intraperitoneal administration of a combined CDDP, 5-FU and MMC therapy for pseudomyxoma peritonei].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Cisplati | 1999 |
[A case of unresectable gallbladder cancer responding to combination therapy with hyperthermia and local chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2000 |
Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Can | 2000 |
Treatment of peritoneal carcinomatosis with intent to cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colorectal Neoplasms; Combined | 2000 |
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Chem | 2000 |
[Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin | 2000 |
Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Region | 2000 |
Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Admin | 2000 |
Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2001 |
Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2001 |
Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 2001 |
Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Digestive Syste | 2001 |
Disseminated peritoneal adenomucinosis associated with a panperitonitis-like onset: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Combined Modality Therapy; Diagn | 2001 |
Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients.
Topics: Adenocarcinoma, Mucinous; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2001 |
Prophylaxis of peritoneal carcinomatosis in experimental investigations.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Fluorouracil; Infusions, Parenteral; Male | 2001 |
[Efficacy of intraperitoneal chemotherapy for peritoneal recurrence of gastric carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2001 |
Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemotherapy, Cancer, Regio | 2002 |
Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2002 |
Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Digestive System S | 2002 |
[Three cases of recurrent gastric cancer responding to TS-1 therapy following combination therapy with 5-fluorouracil, mitomycin C and cisplatin].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administ | 2002 |
Evaluation of intraoperative intraperitoneal cytology for advanced gastric carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Car | 2002 |
Mesorectal microfoci adversely affect the prognosis of patients with rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 1992 |
[Effective treatment of liver metastasis and peritoneal dissemination of gastric cancer using intra-arterial therapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Drug Administration Schedule; Fluoro | 1992 |
[Large volume intraperitoneal chemotherapy as treatment for the peritoneal carcinomatosis from gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Screening Assays, Antitumor; Female; | 1992 |
[Experimental chemotherapy of peritoneal carcinomatosis of colonic origin in rats].
Topics: Animals; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Disease Models, Anim | 1992 |
Anaesthesia for intraperitoneal hyperthermic perfusion.
Topics: Acid-Base Equilibrium; Aged; Anesthesia, General; Combined Modality Therapy; Female; Humans; Hyperth | 1992 |
[Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms].
Topics: Ascites; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Interferon- | 1991 |
[Treatment of gastric cancer patients with peritoneal metastasis by continuous hyperthermic peritoneal infusion with mitomycin C and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Hyperthermia, Induced; Infusions, | 1991 |
[Prevention of peritoneal dissemination after colorectal surgery--significance of MMC administration in abdominal cavity].
Topics: Ascitic Fluid; Colon; Colonic Neoplasms; Humans; Infusions, Parenteral; Mitomycin; Mitomycins; Perit | 1991 |
Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusi | 1991 |
Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation.
Topics: Adult; Cisplatin; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Kidney; Laparoto | 1990 |
Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colonic Neoplasm | 1990 |
[Clinical results of intraperitoneal hyperthermic perfusion combined with surgery in patients with peritoneal recurrence from gastric cancer].
Topics: Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middl | 1990 |
[Pharmacokinetics and prophylactic effect of intraperitoneal administration of mitomycin C resulting in IC50 of gastric cancer].
Topics: Cell Division; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Infusions, Parenteral; Ly | 1990 |
[Evaluation of pluronic F127 as a base for gradual release of anticancer drug].
Topics: Animals; Delayed-Action Preparations; Infusions, Parenteral; Liver; Mice; Mitomycin; Mitomycins; Per | 1990 |
[Intraoperative intraperitoneal administration of mitomycin C and OK-432 for peritoneal dissemination of gastric cancer].
Topics: Adult; Aged; Biological Products; Female; Gastrectomy; Humans; Infusions, Parenteral; Intraoperative | 1990 |
[Clinical evaluation of recurrent patterns of gastric cancer after intraperitoneal hyperthermic perfusion].
Topics: Aged; Ascitic Fluid; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Pa | 1990 |
[Clinical effect of intraperitoneal hyperthermochemotherapy on the survival rate for advanced gastric cancer patients].
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; | 1990 |
[Evaluation of the liver and peritoneal metastasis in the treatment of gastric carcinoma with intra-arterial injection in terms of survival period].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Int | 1990 |
Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies.
Topics: Chromatography, High Pressure Liquid; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neop | 1990 |
[An unresectable colon cancer with a diffuse metastases that turned resectable following thermotherapy with chemoimmunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 1990 |
[A case of nonresectable gastric cancer completely responding to combined chemotherapy according to the mode of progression].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1990 |
[Intraoperative chemotherapy against peritoneal dissemination of gastric cancer with intraperitoneal activated carbon particles adsorbing mitomycin C].
Topics: Adsorption; Carbon; Gastrectomy; Humans; Intraoperative Care; Mitomycin; Mitomycins; Neoplasm Seedin | 1989 |
Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer.
Topics: Adult; Blood Proteins; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female; | 1989 |
Pharmacokinetic analysis in intraperitoneal hyperthermic chemotherapy of far-advanced gastric cancer patients.
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female; Humans; Hyperthe | 1989 |
[Clinical evaluation of intraperitoneal hyperthermic perfusion in far-advanced gastric cancer].
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Evaluation Studies | 1989 |
[Intraoperative chemotherapy with intraperitoneal activated carbon particles adsorbing mitomycin C against peritoneal dissemination of gastric cancer].
Topics: Absorption; Aged; Carbon; Combined Modality Therapy; Gastrectomy; Humans; Intraoperative Care; Mitom | 1989 |
[Continuous hyperthermic peritoneal perfusion with cisplatin and mitomycin C for peritoneal dissemination in gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; | 1989 |
[A case of peritoneal malignant mesothelioma with disappearance of ascites result of intraperitoneal instillation of mitomycin C and oral administration of UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cryptorch | 1989 |
Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding.
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female; Humans; Hy | 1988 |
Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery.
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Carcinoma; Combi | 1988 |
Intraoperative chemotherapy with carbon particles adsorbing mitomycin C for gastric cancer with peritoneal dissemination in rabbits.
Topics: Adsorption; Adult; Aged; Animals; Antineoplastic Agents; Carbon; Female; Humans; Intraoperative Peri | 1988 |
[Extended treatment for gastric cancer patients with peritoneal seeding].
Topics: Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middl | 1988 |
[Prophylactic and therapeutic continuous hyperthermic peritoneal perfusion for peritoneal metastases of gastric cancer].
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; Mi | 1985 |
[Chemotherapy of carcinomatous peritonitis and carcinomatous pleuritis by using activated charcoal particle adsorbing mitomycin C (MMC-CH)--studies on the clinical trials].
Topics: Animals; Carcinoma; Charcoal; Dosage Forms; Humans; Mitomycin; Mitomycins; Peritoneal Neoplasms; Ple | 1985 |